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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
The immune system consists of lymphoid organs and a heterogeneous 
group of motile cell types that are involved in the defense of the body against 
invasion by bacteria, viruses and other foreign bodies.1 
Dendritic cells form a system of antigen presenting cells that is widely 
distributed in the body. They constitute trace population in lymphoid and non-
lymphoid   tissues and in the circulation. They are characterized by their typical 
dendritic and “veiled” morphology, by their constitutive of high levels of major 
histocompatiblity complex class II molecules on their surface, and their 
outstanding capacity to initiate primary immune responses. 
Dendritic cells occur in two states of differentiation. In the immature state 
they are highly specialized for processing foreign protein antigens; in the mature 
state, they efficiently stimulate resting antigen- specific T cells. 
Dendritic cells can migrate from the non-lymphoid tissues, where they 
reside in immature state, via the afferent lymphatics or blood to the T cell 
dependent areas of lymphoid organs like lymph nodes and the spleen. There, 
they appear as mature dendritic cells.  
Therefore dendritic cells are ideally suited to mediate important aspects of 
immunogenicity: they can acquire antigens in the tissues and process them in an 
immunogenic form; they can carry that immunogens to the lymphoid organs; and 
they can find and efficiently activate antigen-specific T cell clones and thus 
generate an immune response.2 
Langerhans cells have been well documented in the epidermis of skin and 
are considered to be the sentinel cells of the cutaneous immune system. 
Innumerable studies have been done describing their number, morphology and 
distribution in the skin, but the knowledge regarding their role in the tympanic 
membrane is very limited. 
There has been some controversy regarding the presence and distribution 
of Langerhans cells in the normal human tympanic membrane. They have been 
reported in the tympanic membranes of patients with chronic otitis media, 
especially in those with aural cholesteatoma. However, the increase in the 
number of Langerhans cells in these conditions has not been quantified. 
A standard technique of identifying the Langerhans cell has been shown 
to be by immunohistochemical testing for the cell surface antigen CD1a. 
This study proposes a morphometric analysis, looking at the number and 
morphology of Langerhans cells in the stratified squamous epithelium and sub-
epithelial connective tissue of normal human tympanic membranes, as well as 
tympanic membranes from individuals with chronic ear infection by 
immunohistochemical testing for the cell surface antigen CD1a, and thereby 
establishing their role in the immunology of the disease. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
Aim: To quantitatively analyze, and to study the distribution and morphology of 
CD1a positive Langerhans cells in normal cadaveric and diseased human 
tympanic membrane. 
 
Objectives: 
 
1. To confirm the presence of CD1a positive Langerhans cells in normal 
human tympanic membrane. 
 
2. To study the distribution and morphology of CD1a positive Langerhans 
cells in normal human tympanic membrane.  
 
3. To study the distribution and morphology of CD1a positive Langerhans 
cells in tympanic membranes of patients with chronic otitis media of both 
the tubotympanic and atticoantral varieties. 
 
4. To quantify the number of CD1a positive Langerhans cells in normal 
versus diseased tympanic membrane. 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. REVIEW OF LITERATURE: 
 
3.1: DENDRITIC CELLS: 
Immunity is the ability of the body to defend itself against invading agents 
such as bacteria, toxins, viruses and foreign tissues. At the core of the immune 
system is the ability to distinguish “self” and “non self”.  
Classically, the immune response has been differentiated into innate 
immunity and acquired immunity.  In general, immunity consists of two closely 
allied components. One consists of the formation of specially sensitized 
lymphocytes that have the capacity to attach to the foreign agent and destroy it. 
This is called cellular or cell mediated immunity. The other consists of 
circulating antibodies produced by the body that are capable of neutralizing, 
eliminating or rendering ineffective an invading agent. This is called humoral or 
antibody mediated immunity. 
 Unlike B cells, T cells can only detect foreign substances in specific 
contexts. In particular, T lymphoytes will recognize a foreign protein only if it is 
first cleaved into small peptides, which are then displayed on the surface of a 
second host cell called an antigen presenting cell.3 
The macrophage is the typically described antigen presenting cell. 
However, there is one function where it is deficient, namely, the priming of naive 
lymphocytes. It is believed that cells other than macrophages prime T helper 
cells and these are the dendritic cells.1 
Dendritic cells are a system of antigen presenting cells that function to 
initiate several immune responses such as the sensitization of MHC-restricted T 
cells, the rejection of organ transplants, and the formation of T-dependent 
antibodies.4 They are so named because of their long dendritic processes that 
can be visualized with special stains under light microscopy.5, 6 
It is the wide distribution of dendritic cells in vivo that renders them 
especially suited to capture antigens, and subsequently to sample and select T 
cells with reactivity for that antigen.7 To state a few examples, dendritic cells are 
distributed throughout the suprabasal zone of the epidermis and in other stratified 
squamous epithelia,8 they are found in airways, 9-11 gut mucosa12, 13 and in the 
interstitial spaces of most other organs other than the parenchyma of the brain.14, 
15 Dendritic cells are also frequently found in afferent lymphatics where they are 
called “veiled” cells.16, 17 In addition, both immature and mature dendritic cells are 
found in the blood.7, 18, 19 This is due to their unique capacity to migrate from 
tissues where they have first encountered an antigen, to T cell areas of lymphoid 
tissues.20 Dendritic cell migration via the blood provides access to peri-arterial 
sheaths of T cells in the spleen, while their migration through the afferent lymph 
vessels provides access to the para-cortical cells of the lymph node. The T cell 
areas are not static zones. On the contrary, T cells continually re-circulate 
through these regions. In doing so, they encounter the numerous antigen-major 
histocompatability complex rich processes of the dendritic cell. This enhances 
the ability of dendritic cells to select those T cells that are specific for the 
antigens being presented. Dendritic cells also home to sites of delayed 
hypersensitivity where they again closely associate with T cells.21  
 
Types of dendritic cells: 
Dendritic cells exist in different forms in different tissues. Broadly, they can 
be classified into four types, namely3: 
a. Langerhans cells of the epidermis: These are situated in the suprabasal 
portions of the epidermis and have been described in detail later in this 
document. 
 
b. Blood dendritic cells: Human blood contains two subsets of dendritic 
cells, namely, an immunologically mature type, having powerful 
immunostimmulatory function and an immunologically immature type. O’ 
Dohertry et al18, 19 hypothesized that the immature cells are marrow-
derived precursors to tissue dendritic cells, such as epidermal 
Langerhans' cells. It is also stated that the mature cells are derived from 
tissues where they have been activated by an antigen and are en route to 
the spleen or lymph nodes to stimulate T-cell responses there. Purified 
fresh isolates lack the characteristic morphology, phenotype, and 
immunostimulatory function of dendritic cells. When placed in culture, the 
cells mature in a manner resembling the cytokine-dependent maturation of 
epidermal dendritic cells (Langerhans cells). The cells enlarge and exhibit 
many cell processes, express much higher levels of major 
histocompatibility complex class II and a panel of accessory molecules for 
T cell activation, and become potent stimulators of the mixed leukocyte 
reaction. 
 
c. Veiled cells of the lymph: These constitute the cells migrating via the 
afferent lymphatics towards lymphoid tissue. 
 
d. Interdigitating cells of lymphoid organs: In the thymus, dendritic cells 
are confined primarily to the medulla where they are responsible for self 
tolerance.7 Thymic dendritic cells process self-antigens and mediate the 
deletion of self-reactive T cells.22, 23 In the thymic medulla, and in the T cell 
areas of peripheral lymphoid organs, these dendritic cells have been 
called interdigitating cells.17 
 
Despite their many names, all the different mature members of the 
dendritic cell family can exhibit similar features.7  
In contrast, there exists a different type of dendritic cell found in the B cell 
areas of follicles of lymphoid organs. These are called follicular dendritic cells 
which are large, non-lymphoid cells with elongated cytoplasmic extensions that 
form the framework of the germinal centre.24 They are thought to be stromal 
rather than myeloid cells.25 They play a central role in events related to humoral 
immunity in the lymphoid follicle.26, 27 Follicular dendritic cells function to present 
antigens as immune complexes to B cells, rather than processed antigens as 
MHC-peptide complexes to T cells.  
CD1a antigens are present on Langerhans cells and interdigitating cells 
but not on follicular dendritic cells, reinforcing that Langerhans cells and 
interdigitating cells are close relatives but despite their name, follicular dendritic 
cells may be regarded as a different cell type.28, 29 In addition, follicular dendritic 
cells do not have the typical Birbeck granules in their cytoplasm which distinguish 
them from Langerhans cells.24 
Apart from the stratified squamous epithelium of skin, dendritic cells are 
also seen scattered through the dermis or subepithelial connective tissue. The 
origin of these dermal dendritic cells is controversial, as these cells are CD1a 
positive but lack Birbeck granules which are characteristic of Langerhans cells. 
Thorbecke et al30 reported that the dendritic cells found in the subepithelial 
connective tissue were similar to Langerhans cells, and they stated that CD1a 
positivity further re-emphasised their similarity. Lenz et al studied dendritic cells 
cultured from human and murine dermis. They postulated three theories based 
on these findings regarding the origin of the dermal dendritic cells. a) They may 
originate from epidermal Langerhans cells or their precursors on their way into 
the epidermis. b) Alternatively, they may originate from epidermal Langerhans 
cells on their way from the epidermis to the draining lymphnodes. c) Finally, the 
majority of dermal dendritic cells may be derived from a resident population of 
presumably immature dendritic cells in the dermis, analogous to the population of 
Langerhans cells in the epidermis.5 
3.2: THE LANGERHANS CELL: 
3.2.1: History: 
The Langerhans cell of mammalian stratified squamous epithelia has 
intrigued morphologists for many years. Since their discovery in the skin as a 
distinct cell population with characteristic cell processes more than a century 
ago, these cells remained unstudied until a few decades ago.31 
Epidermal Langerhans cells were first described in 1868 by Paul 
Langerhans (born Berlin, Germany, 25 July 1847; died Funchal Madeira, 20 July 
1888), the son of a well know physician in Berlin, who studied medicine at the 
Universities of Jena and Berlin, graduating in 1869. He made an outstanding 
contribution to medicine while still an undergraduate student when he described 
a new epidermal cell in a paper entitled, “Ueber die Nerven der menschlichen 
llaut”, 31 which when translated from German reads, “On the nerves of the human 
skin”. Using gold chloride techniques, he described the dendritic non-pigmentary 
cells in the epidermis, which he regarded as intraepidermal receptors for 
extracutaneous signals of the nervous system. These cells were subsequently 
designated with his name.32 
In 1959, Silvers33 first demonstrated that aurophilic dendritic cells of the 
epidermis were not of neural crest origin and were thus, not related to 
melanocytes.34 
Birbeck et al35 later used electron microscopic techniques to show that 
Langerhans cells contain a characteristic organelle referred to as the Birbeck 
granule or the Langerhans cell granule. 
However, the physiological role of these cells remained unknown for a 
long time.  
In 1973, Inga Silberg36 discovered that the epidermal Langerhans cells 
represent the most peripheral outpost of the immune system. Only subsequently 
were they identified as dendritic cells that reside in the epidermis in an immature 
state, but have the capacity to migrate and develop into mature lymphoid 
dendritic cells. 32 
 
3.2.2: Location and distribution: 
Langerhans cells are widely distributed in the body. They are situated in 
the suprabasal portions of the epidermis.2, 4, 37 
Cell-kinetic studies have established the origin of the Langerhans cell. 
After allogenic bone marrow transplants, Langerhans cells are seen to be 
completely replaced by donor cells within a few weeks. This has provided the 
basis for the concept that Langerhans cells are derived from a mobile pool of 
bone marrow derived precursors that are constantly recruited to the skin.38, 39  
Under normal circumstances, the turnover rate is slow. Mitoses of 
Langerhans cells are rare. However they are probably continually renewed and 
replaced in the periphery of the body.  
They are present in any stratified squamous epithelium, of either 
ectodermal or endodermal origin, which has the capacity to keratinize.40  
Bauer et al,41 in a study of mammary skin using a confocal laser scanning 
microscope, found that a strikingly constant ratio between Langerhans cells and 
other epidermal cells in healthy skin is maintained. Thus, the variation in surface 
density from area to area can be explained by the varying thickness of the 
epidermis. 
 
3.2.3: Function of the Langerhans Cell: 
The physiological role of Langerhans cells remained unknown for a long 
time. Detection of Fc-Ig and C3 receptors42 and Ia antigen43, 44 established the 
cell as a form of specialized epidermal macrophage. Recent studies now suggest 
that these cells act constructively as antigen presenting cells in the 
immunological reactions of the skin.45 
As members of the dendritic cell family of antigen presenting cells, 
Langerhans cells have crucial roles in the initiation of cellular immune responses 
to environmental antigens.6, 8, 46, 47 Epidermal Langerhans cells are thought to be 
sentinel cells of the cutaneous immune surveillance system.45 Upon activation, 
they increase their expression of MHC class II.48 They appear to recognize 
antigens and present them to T lymphocytes, and possibly macrophages.49, 50 
Evidence suggests that they may produce lymphokines, hydrolytic enzymes and 
even prostaglandins.30  
Research by Hunger et al51 indicates that the function of antigen 
presentation in Langerhans cells is mediated by the Langerhans cell-specific 
pattern recognition receptor, langerin, as well as the antigen presenting molecule 
CD1a, which is highly expressed by these cells. 
Langerhans cells and thymus derived T lymphocytes have always had a 
special affinity for each other. Experimental evidence indicates that Langerhans 
cells migrate through the afferent lymphatics to the draining lymph nodes,37, 52 
carrying antigenic information on their cell membrane. T-cells will then respond 
and multiply.53 By re-circulating through the body, these cells will meet their 
challengers again in the periphery. Evidences for the fact that these cells are 
capable of movement are many.30 Ultrastructurally, they sometimes display 
networks of microfilaments54 with dimensions of actin as well as a prominent 
system of microtubules55. These features are usually found in cells that move. 
Work by Kripeke et al56 and others16, 57 showed that following topical sensitization 
of nude mice at the site of an allogenic graft, the antigen-bearing dendritic cell 
found within the draining nodes were of graft donor origin, giving a compelling 
argument that epidermal Langerhans cells are stimulated to migrate via afferent 
lymphatics to the draining nodes. During this migration, they undergo a process 
of maturation that allows them to present antigens to naïve T cells. Data from 
these studies shows that Tumor Necrosis Factor α produced locally by 
keratinocytes is, possibly, one stimulus for migration from the skin. 
Epidermal Langerhans cells resemble macrophages in several remarkable 
respects,45, 58 for instance, in the presence of Fc and C3 receptors.42 In addition 
to the remarkable similarities in their surface markers, there are also analogous 
roles for these two cells in the initiation of immune responses.9 In vitro studies 
have demonstrated that antigen-pulsed, Langerhans cell enriched epidermal cell 
preparations can induce proliferative responses in immune T cells that are 
comparable in magnitude to those induced by similarly pulsed macrophages.49 
Frequent close apposition of Langerhans cells to lymphocytes has been 
observed at sites of contact hypersensitivity reactions, as well as increased 
numbers of Langerhans cells observed in dermal lymphatics and draining 
lymphnodes in these conditions.40, 52, 59 These observations have lead to the 
proposal that Langerhans cells pick up antigens in skin and from there move to 
draining lymph nodes, where they present the antigen to immunologically 
relevant cells stimulating the resulting T cell response.60  
 
 3.2.4: Structure: 
In routine histological sections stained with hematoxylin and eosin, 
Langerhans cells cannot be selectively identified. Enzyme histochemical and 
electron microscopic studies, however, have demonstrated that these cells are 
suprabasal dendritic cells within the epidermis, and their branched and tapering 
processes extend far into the surrounding epithelium.61 They are characterized 
by their typical dendritic and veiled morphology and by their expression of major 
histocompatibility complex II.37  
Figueroa and Caorsi62 reported an ultrastructural and morphometric study 
of the Langerhans cells in the normal human exocervix. They classified the 
Langerhans cells seen into five types, based on the characteristics of the 
dendritic processes, as follows:  
Type I: Only one, unbranched process 
Type II: Only one process which divides into branches 
Type III: 2 processes 
Type IV: Three or more processes 
Type V: Also with 3 or more processes but with several collaterals, these, 
in turn, branched dichotomously. 
On an ultrastructural level, Langerhans cells are described to have a 
lobulated nucleus and lack desmosomes as well as tonofilments. Their cytoplasm 
contains a well-developed Golgi apparatus, endoplasmic reticulum, mitochondria, 
centrioles and lysosomes. Most importantly, they produce characteristic granules 
called Birbeck granules.63  
Birbeck granules: 
Birbeck and coworkers described a specific organelle by which 
Langerhans cells can be identified at the submicroscopic level, as distinctive rod-
shaped or tennis racket-shaped structures of variable length with a central, 
periodically striated lamella.35  
Wolff63 then went on to describe the fine structure of the Birbeck granule 
from Langerhans cells in the human skin. These granules exhibit different 
morphological features in different planes of section. Their most common 
electron microscopic image is that of a rod-like profile with round ends and a 
limiting membrane approximately 55-60Ǻ thick. Midway between the limiting 
membranes is a central lamella composed of electron-opaque particles. Owing to 
the regular spacing of these particles, the rod-like structures acquire a definite 
pattern of cross-striation. These profiles are very often continuous with round 
vesicles and thus resemble tennis rackets. Usually the vesicle is located at one 
end of the granule, but may also be seen in its centre, with the rod-like structures 
projecting from its circumference. The large majority of the Langerhans cell 
granules are seen in the golgi region, but they can also be seen in other areas of 
the cytoplasm and in the dendritic processes. Not infrequently, the granules are 
attached to the plasma membrane and their interior is continuous with the 
extracellular space. 
Conflicting theories exist regarding the derivation and function of these 
granules.64 The secretion or exocytosis theory suggests they have an 
intracellular origin from either the Golgi apparatus or endosomes.63, 65, 66  
Alternatively, the endocytosis theory suggests that Birbeck granules 
originate from the cell membrane, during receptor-mediated endocytosis, as a 
prolongation of coated pits that pinch off to form intracellular Birbeck 
granules.67,68  
 
3.2.5: Methods available for identification of Langerhans cells: 
Routine histological staining techniques do not visualize the Langerhans 
cell. However, newer methods of identification have improved this picture. 
A definitive technique of identification of these cells would be by identifying 
the Birbeck granules on an ultrastructural level.35 This however, requires electron 
microscopy which is not always a practical option. 
Some techniques that have been useful in visualization under light 
microscopy include staining with Gold chloride,31 ATPase staining69, 70 and the L-
dopa fluorescence method.71  Juhlin and Shelley described a technique of 
staining with a combined stain of adenosine triphosphate and gold.59 These 
techniques present problems with the specificity of reaction and complication of 
procedure. 
Another useful technique is staining with zinc iodide-osmium tetroxide.72 
However, apart from dendritic cells, this has been shown to stain nervous tissue 
and fat. 
Interest in the role of epidermal Langerhans cells in cutaneous immune 
reactions was stimulated in 1977 by the discovery that these cells express 
surface markers characteristic of cells of the macrophage-monocyte lineage.42-44, 
56 A number of antigenic markers have been identified on the cell surface of 
Langerhans cells, some more specific than others. These are S-100 protein,73, 74 
HLA-DR, CD1a,30, 34, 38, 43, 44, 59, 75, 76 Langerin,77 E-Cadherin,78 etc.  
Of these, S100 protein is less specific for Langerhans cells than CD1a 
because it is also present in Schwann cells, fat cells, chondrocytes, interstitial 
cells of the pineal gland, stellate cells of the adenohypophysis, satellite cells of 
the adrenal medulla etc.74, 79 Studies by Palva and Taskinen59 and Harrist et al80 
showed that CD1a is a better marker for Langerhans cells than HLA-DR, as not 
all Langerhans cells are positive for HLA-DR antigens. Another drawback of 
HLA-DR labeling is that other inflammatory cells that may infiltrate the epidermis, 
such as B cells, some activated T cells and mononuclear phagocytes, also 
express the HLA-DR antigen. 
Thus the most sensitive markers for Langerhans cells are believed to be 
CD1a and Langerin.64 Notably, Langerhans cells are the only epidermal cells to 
constitutively express MHC class II molecules,43, 44 CD1a molecules75 and 
Langerin81 at their cell surface.  
 
CD1a staining: 
Where a cluster of monoclonals are found to react with the same 
polypeptide, they clearly represent a series of reagents defining a given marker 
and are labeled with a CD (cluster of differentiation) number. Currently there are 
nearly 340 CD numbers assigned, with some of them having subdivisions. The 
CD1 group presents glycolipid and other non-pepitde antigens to T cells.1 Human 
CD1 antigens are a family of structurally related glycoproteins that are non-
covalently associated with β2 microglobulin on their cell surface like MHC class I 
molecules.82-84 They are encoded by a set of genes on chromosome 1 in 
humans. They are involved in the presentation of antigens to T cells.  
At least 5 different CD1 genes have been identified and sequenced,85 of 
which three express homologous proteins, CD1a (49kd), CD1b (45kd) and CD1c 
(43 kd) molecules respectively.86 These subsets are found on cortical 
thymocytes, dendritic cells and a subset of B cells. These antigens can be 
detected serologically and many different monoclonal antibodies are available for 
each subgroup.87 Langerhans cells express CD1a molecules at exceptionally 
high levels with virtually no CD1b and only modest CD1c expression, whereas 
other dendritic cell subsets predominantly display CD1b molecules with varying 
degrees of CD1a and CD1c expression.83  
A positive staining reaction with CD1a (also called OKT6/Leu6) is 
considered by some as the gold standard for Langerhans cell identification, 
despite the fact that this epitope is also present in the cortical thymocyte 
because, with maturation, cortical thymocytes lose CD1a before exiting the 
thymus.45, 88  
 
3.2.6: Tissues in which Langerhans cells have been found: 
Langerhans cells have been found in a wide variety of tissues, apart from 
the epidermis.88 To site a few examples, the buccal mucosa,89 oesophagus,90 
lungs,10, 11, 88  female genital tract,91, 92 conjunctiva,93 palatine tonsil,94 nose,95, 96 
larynx and hypopharynx,97 vocal cords,98 hair follicle,99 etc.  
Langerhans cells have also been found to secrete a variety of cytokines 
that are important in the pathogenesis of contact dermatitis, atopic dermatitis,100, 
101 histiocytosis X, HIV-1 infection and skin graft rejection.88, 102   
Increased numbers of Langerhans cells have been found associated with 
a number of conditions88 like lichen planus, 103-105 in the peripheral blood of 
patients with burns and trauma,106, 107 in the epithelial surface of the lower 
respiratory tract in cigarette smokers,108 in the conjunctiva of patients with 
contact dermatitis,60, 109, 110 etc. Langerhans cells have also been implicated in 
the etiology of neoplastic transformation in immunocompromised individuals.111  
The numbers of Langerhans cells have been found to be decreased in 
various conditions like cutaneous lupus erythematosus,112 ultraviolet radiation,113 
ageing114, 115 skin carcinoma,116, 117 basal cell carcinoma of face and trunk,118 
cervical condyloma and intra epithelial neoplasm,119 etc. 
 
3.3: CHRONIC OTITIS MEDIA: 
The diagnosis of chronic otitis media implies a permanent abnormality of 
the pars tensa and pars flaccida, most likely a result of earlier otitis media, 
negative middle ear pressure or otitis media with effusion. Chronic otitis media 
equates with the earlier term chronic “suppurative” otitis media that is no longer 
advocated as chronic otitis media is not necessarily a result of gathering of 
pus.120 
Classically, chronic otitis media is divided into 2 types: 
Tubotympanic disease: also called safe or benign type. It usually has less 
severe complications. 
Atticoantral disease: It is also called unsafe or dangerous type because of the 
complications associated with it.121 
In the tubotympanic variety of otitis media, there is chronic inflammation 
within the mucosa of the middle ear and mastoid, with varying degrees of 
oedema, submucosal fibrosis, hypervascularity and infiltration with lymphocytes, 
plasma cells and histiocytes. Areas of the mucosa may ulcerate with 
proliferations of the blood vessels, fibroblasts and inflammatory cells, leading to 
the formation of granulation tissue. There is production of mucopurulent 
discharge which drains via a tympanic membrane perforation. The mucosal 
changes may progress and coalesce to form aural polyps that can protrude 
through defects in the tympanic membrane. Thus, simple closure of a perforation 
in active mucosal chronic otitis media without surgical removal of infected 
mucosa and granulation tissue from the mastoid is fraught with failure to control 
the disease.120 
In the atticoantral variety of chronic otitis media, also known as 
cholesteatoma, the hallmark is its retention of keratin debris. Thus, a “keratoma” 
would be, histologically, a more accurate term. The squamous epithelial lining or 
“matrix” of a cholesteatoma is similar to that of skin. The matrix is usually 
surrounded by a layer of inflamed, vascular, subepithelial connective tissue. A 
cholesteatoma can be filled with keratin and be quite dry, or be associated with 
active bacterial infection, leading to profuse, malodourous otorrhoea. 
Cholesteatomas are potentially dangerous because of their potential to incite 
resorption of bone, leading to intratemporal and intracranial complications.120 
The light and electron microscopic findings in a human cholesteatoma 
matrix have been studied in detail. The cellular composition of the matrix and its 
adjacent mucosal lining is not static but undergoes permanent changes in terms 
of cells moving from the circulation in and out of this area. Migrant lymphoid and 
non lymphoid cells (Langerhans cells, monocytes) presumably play a key role in 
the natural history of the disease.40 
Understanding of the destructive properties of cholesteatoma has been 
progressively clarified in the last few decades. Theories of avascular pressure 
necrosis have been replaced by the concept that complex cellular and chemical 
events of chronic inflammation induce bone breakdown. Mononuclear 
inflammatory cells in the subepithelial granulation tissue zone of the 
cholesteatoma generate collagenase and lysosomal enzymes. Prostaglandins 
and other demineralizing factors also participate in the localized bone resorptive 
process. Epidermal Langerhans cells also play an important role. It appears that 
Langerhans cells initiate an immunologic response in the presence of antigens. 
The outcome of this reaction is an inflammatory reaction. In cholesteatoma, the 
inflammatory reaction is unable to correct the anatomical deformity of the 
retraction pocket. Therefore, it becomes chronic. This may stimulate a local 
hypersensitivity state and further propagation of the inflammation. New 
knowledge of the immunologic function of the epithelium, especially of epidermal 
Langerhans cells, may enable us to determine the role of the epithelium in 
cholesteatoma formation.122 
 
3.4: CURRENT KNOWLEDGE BASED ON RESEARCH DONE ON THE 
TYMPANIC MEMBRANE: 
 
3.4.1: Structure of the tympanic membrane: 
The tympanic membrane separates the tympanic cavity from the external 
acoustic meatus. It is thin, semi-transparent and almost oval, somewhat broader 
above than below. It lies obliquely at an angle of about 55° with the meatal floor. 
At most of its circumference is a thickened fibrocartilaginous ring or annulus 
which is attached to the tympanic sulcus at the medial end of the meatus. The 
sulcus is deficient superiorly, resulting in the formation of the anterior and 
posterior mallear folds from the edges of the notch to the handle of the malleus. 
The pars flaccida is the small triangular part of the membrane which lies above 
these folds, and is lax and thin. The rest and major part of the membrane is the 
pars tensa which is taut.123 
There have been numerous investigations on the structure of the tympanic 
membrane under light and electron microscopy. 
Histologically, it is composed of three strata: an outer cuticular layer, an 
intermediate fibrous layer and an inner mucous layer. The cuticular stratum is 
continuous with the thin skin of the external acoustic meatus. It is keratinized, 
stratified squamous in type and is hairless. The mucous stratum is part of the 
mucosa of the tympanic cavity, consisting of a single layer of flat cells.123 
Lim DJ124, 125 described the ultrastructure of the pars tensa and pars 
flaccida of the tympanic membrane in guinea pigs, cats, squirrel monkeys, 
rabbits, and sheep. Lildholdt et al126 described the ultrastructure of the tympanic 
membrane in the rhesus monkey. Johnson et al127 and Schmidt and Hellstrom128 
also described its ultrastructure in the guinea pig. Detailed descriptions of the 
human tympanic membrane were done by Hentzer129 and Lim DJ.130 A summary 
of their findings is as follows. 
In the pars tensa of the tympanic membrane, three layers were distinctly 
recognized, an outer epidermal, a middle lamina propria and an inner mucous 
layer. The epidermis was reported to be divided into (1) stratum corneum, (2) 
stratum granulosum and (3) stratum Malpgii, which was further divided into 
stratum spinosum and stratum basale. There was no evidence of a stratum 
lucidum. The epithelium was said to rest on a continuous basement membrane 
was reported to lack the characteristic epidermal rete pegs seen in the skin.  
The lamina propria was subdivided into (1) subepidermal connective 
tissue, (2) radiate collagenous bundle layer, (3) circular collagenous bundle layer 
and (4) submucosal connective tissue layer. 
The mucous layer was described to be composed of simple squamous to 
cuboidal epithelial cells, sometimes with and sometimes without cilia. 
Pars Flaccida: In 1830, Shrapnell first described the pars flaccida of the 
mammalian tympanic membrane and hence it was named after him (Shrapnell’s 
membrane).131 He described this portion of the tympanic membrane as being 
more elastic than the pars tensa. Some subsequent authors felt that this part of 
the tympanic membrane lacked a lamina propria. However, Lim DJ125 described 
the pars flaccida of the tympanic membrane as having three layers, like the pars 
tensa. He said the epidermal and mucosal layers were similar in structure to that 
of the pars tensa and that the lamina propria was present. However, the compact 
fibrillar bundles of radial and circular fibres were missing completely. There was 
no clear-cut morphological distinction between the subepidermal and 
submucosal connective tissue layers. 
In a comprehensive electron microscopic study of human tympanic 
membrane, Lim DL et al,130 in 1970, described in the basal portion of epidermis a 
cell that did not possess characteristics of an epithelial cell. In retrospect it is 
thought that this cell was probably a dendritic cell. 
 
3.4.2: Studies involving Langerhans cells in the tympanic membrane: 
Animal experimental studies: 
Forséni et al132 studied the tympanic membrane in rats. In this study, 
experimental otitis media was produced in Sprague Dawley rats by inoculation 
with Streptococcus pneumoniae, acute otitis media was confirmed by observing 
the tympanic membrane with an operating microscope. A temporal study was 
done on days 3, 6 and 10, using immunocytochemical markers to map out the 
inflammatory cells seen. The results of this study with regards to the dendritic 
cells was that their numbers were maximum on day 3, still abundant on day 6 
and fewest on day 10, but these cells were noted maximally in the  subepithelial 
connective tissue. Very few were seen in the epithelial layer.  The normal 
tympanic membrane was not seen to have these cells. 
Ichimiya et al133 studied the immunological potential of the tympanic 
membrane in mice by staining normal and inflamed tympanic membrane by 
immunocytochemical techniques. Here healthy BALB/c mice were used and 
experimental otitis media induced on one side. Quantitative assay of IgA positive, 
CD4 positive, CD1a positive and mast cells was done in both infected and control 
ears. Observations were made in the middle ear mucosa as well as the tympanic 
membrane. In this study, the normal tympanic membrane showed far less 
infiltration than the middle ear mucosa. CD1a positive cells were absent in the 
normal tympanic membrane except in the pars flaccida, and in the 
manubrial and annular parts of the pars tensa. The rest of the pars tensa was 
devoid of Langerhans cells. In the tympanic membranes in which otitis media had 
been induced, there was an overall increase in CD1a positive cells. The pars 
tensa this time showed cells. There were also cells seen in the subepithelial 
tissue. Overall, the middle ear mucosa showed far more cells than the tympanic 
membrane. In this study, quantitative analysis of cells was done, comparing Ia, 
mast, CD4 and IgA positive cells. They concluded that the pars flaccida, and the 
manubrial and annular parts of the pars tensa are immunologically potential sites. 
The rest of the tympanic membrane shows immunologic response because of 
migration of Langerhans cells through the tympanic membrane following 
antigenic stimulation. 
 
Summary of studies on Langerhans cells in the human tympanic 
membrane and middle ear tissue: 
The poor availability of fresh tympanic membrane tissue makes studies on 
the normal tympanic membrane difficult. Studies have been done, however, in 
specimens removed from diseased ears. Langerhans cells have been 
demonstrated in large numbers in the matrix of aural cholesteatomas.40, 73, 134-137 
They have also been found in inflamed tympanic membranes and middle ear 
mucosa.138-140 Based on preceding animal experimental studies, the normal 
tympanic membrane was hitherto thought to be devoid or almost devoid of these 
cells. Two studies have been done on normal cadaveric tympanic membrane, 
one by Hussl et al,37 and the other by Gantz.122 Interestingly, these have 
contrasting findings. These, along with research done on Langerhans cells in 
diseased human tympanic membrane are described below. 
  Palva et al59 studied inflammatory cell subpopulations in chronic otitis 
media. Tissues studied were cuboidal or secretory epithelium, ear canal skin and 
Shrapnell’s membrane, cholesteatoma membrane and open cavity skin in 
revision ears. CD1a positivity and HLA DR positivity were tested for. This study 
showed Langerhans cells in the secretory epithelium, subepithelial lymphoid 
nodules and cholesteatoma epithelium, although they were not seen in the canal 
skin. One Shrapnell’s membrane had no cells, while the other had.  
Veldman40, 133 studied the immunology of cholesteatoma and compared 
human cholesteatoma matrix tissue with normal tympanic membrane and 
external ear skin. Membrane ATPase staining of matrix and submucosal layers of 
cholesteatoma tissue showed the extensive presence of characteristic 
Langerhans cells with their dendritic processes in the epithelial layer. The 
normal tympanic membrane contained hardly any detectable Langerhans 
cells. The external ear skin showed a picture similar to that of normal skin. 
Veldman40 stated that since these cells are hardly present or even absent in the 
normal tympanic membrane, it could be tentatively concluded that they follow a 
change in the nature of such an epithelial lining like an antigenic stimulus, 
retraction pocket or perforation with infection and subsequently enter. He also 
stated that the migratory properties of Langerhans cells would mean that they not 
only move into but also wander out of the matrix back into the patients’ lymphoid 
system. Local production of lymphokines in the Langerhans cell-T cell 
microenvironment would possibly have particular consequences like triggering of 
bone resorption and destruction. If an “irritant” (antigen/hapten) together with the 
local physical state of the tympanic membrane-middle ear complex were 
responsible for the development of the cholesteatoma, then sensitization of the 
lymphocytes of the T lineage would also occur, including memory cell production. 
He concluded that this knowledge was clinically very relevant as meticulous 
surgery to eradicate cholesteatoma, would therefore, not interfere with cells 
already in circulation.  
Studies by van Dijk et al138 showed that Langerhans cells probably play a 
key role in skin-related disorders, including cholesteatomas. He postulated that 
they originate from a mobile cell population of monocyte origin and migrate into 
and out of the body's lining. Since their custodial function is often carried out in 
close relation with T-lymphocytes, he used monoclonal antibodies against 
Langerhans' cells and T-lymphocyte membrane receptors, which revealed the 
presence of these cell populations in cholesteatoma matrices but not in the 
tympanic membrane. He thus said that the Langerhans cells and T-cell traffic 
through cholesteatomas have an important role in relation to the pathogenesis, 
natural course and recurrence of cholesteatomas.  
Shinoda et al141 tried localizing intercellular adhesion molecule-1 (ICAM-1) 
in middle ear cholesteatoma. ICAM-1 appeared to be localized on keratinocytes 
in all layers of the epithelium and on Langerhans cells in both the epithelium and 
granulation tissue of cholesteatoma. ICAM-1 was not found in the epidermis of 
normal external ear canal skin, normal tympanic membrane or normal facial skin. 
This suggested that ICAM-1 may have a role in clinical development of 
cholesteatoma, including migration, adhesion and proliferation of lymphocytes, 
Langerhans cells and keratinocytes.  
Park58 studied the occurrence rate of Langerhans cells in cholesteatoma 
matrix, cavity skin and posterior auricular skin, to evaluate their pathological 
significance. He found that the cholesteatoma matrix was varying in thickness, 
specimens from subjects with the clinical symptom of otorrhoea, tending to have 
thicker epithelium with epithelial and subepithelial inflammatory cell infiltration. 
Numerous Langerhans cells were found in the cholesteatoma matrix, cavity skin 
and posterior auricular skin specimens. Langerhans cells in the 
cholesteatoma and cavity skin were more numerous and had longer 
dendritic processes than those in the preauricular skin. Also, there tended to be 
direct correlation between the number of Langerhans cells and the degree of the 
subepithelial inflammation in the cholesteatoma. 
In the study done by Palva and Taskinen,59 CD1a positive cells were 
found in the subepithelial connective tissue and in lymphoid follicles in the middle 
ear mucosa of cases with chronic otitis media, with and without cholesteatoma. 
Takahashi and Nakano73 demonstrated Langerhans cells in 
cholesteatoma using antiserum against S100 protein. Control specimens were 
normal skin from the external ear and from tympanic membranes of patients 
undergoing surgery for chronic otitis media. They found Langerhans cells 
containing S100 protein immunoreactivity scattered in the epithelium of the ear 
skin and tympanic membrane with otitis media but restricted to stratum 
spinosum. No cells were found in the subepithelial connective tissue. Also, they 
had simpler shape and had fewer dendritic processes than those found in aural 
cholesteatomatous tissue. When the cholesteatomatous tissue was studied, 
numerous S100 positive dendritic cells were recognized. There was an obvious 
increase. However, in these cases only the cholesteatomatous tissue were 
studied and not the tympanic membranes. Those cases with ottorrhoea had more 
cells and the epithelium was thicker. All the cells in the cholesteatomatous tissue 
had well developed dendritic processes, which branched out intricately. 
The processes were mainly directed towards the epithelium. Cells were also 
found in the subepithelial connective tissue. In the cases with ottorrhoea, there 
were areas in the subepithelium with massive lymphocytic infiltration with S100 
positive cells in these infiltrates. On quantification, all controls had less than 20 
Langerhans cells per mm of epithelium, in cholesteatoma with otorrhoea, 33 per 
mm and in cholesteatoma without otorrhoea, 14 per mm. He described the role of 
the Langerhans cells as being antigen presenting cells at these sites. And the co-
localization of Langerhans cells and lymphocytes in the subepithelial region of 
the cholesteatoma suggested that these cells play an important role in the 
immunodefence system. 
In a study done by Hussl et al37 on normal tympanic membranes, 12 
normal cadaveric tympanic membranes from patients who had died of causes 
other than ear disease and had had no history of middle ear diseases, removed 
14-21 hours after death, were studied. The epidermal layer was peeled off and 
stained with the following antibodies: HLA-DR, OKT6/CD1a and LAG. The results 
of this study showed that in the epidermis of all 12, a dense network of cells 
could be demonstrated which were positive for HLA-DR but negative with 
CD1a and LAG antibodies.  However the number of HLA-DR positive cells per 
high power field when compared with retroauricular skin was lower. This was 
however not quantified. On electron microscopy, the structure was found to be 
similar to Langerhans cells except that no Birbeck granules were seen. In 
tissue culture studies typical veiled cells could be recovered from the culture 
medium. They were comparable to defined types of mature dendritic cells such 
as proliferating dendritic cells from the peripheral blood.142 In this study,37 
possible explanations given for CD1a negativity in the normal tympanic 
membrane were: 1. Dendritic cells in the tympanic membrane may have a 
different phenotype than epidermal Langerhans cells, 2. Antigens or epitopes like 
CD1a or LAG  could possibly disintegrate postmortem (>14 hours after death). 
Gantz122 looked at epidermal Langerhans cells in cholesteatoma matrix 
and compared them with normal tympanic membrane and normal ear canal skin. 
Normal ear skin demonstrated Langerhans cells in the suprabasal portion of the 
epithelium. Cell bodies were round with variable number of filamentous dendritic 
processes. Electron microscopy showed Birbeck’s granules. The stratified 
squamous epithelium of the normal tympanic membrane also contained 
Langerhans cells, but they were fewer in number than in the ear canal skin and 
had an elongated appearance. Although Gantz reported the presence of these 
cells in the normal tympanic membrane, quantification of the cells per unit 
length or quantitative comparison between inflamed tympanic membrane 
was not done. The other different finding was that Langerhans cells were evenly 
distributed through the entire surface of the tympanic membrane and not limited 
to the pars flaccida and the annular and manubrial regions of the pars tensa, as 
has been suggested by others like Ichimiya et al.133, 143 Cholesteatoma matrix 
showed increased number of Langerhans cells compared to the other two 
(again quantification not done). In the cholesteatomatous tissue, he reported that 
the Langerhans cells were at variable levels of the epithelium and not confined to 
the suprabasal portions. On electron microscopy, the cells looked strikingly 
different from the normal tissue. They were elongated cells, closely apposed to 
lymphocytes. Increased mitochondria, multiple golgi apparatus and increased 
secretory vacuoles indicated increased secretory activity.  
Veldman et all,138 Gantz122 and Takahashi and Nakano,73 all suggested 
that Langerhans cells within the cholesteatoma matrix were responsible for 
generating and maintaining the chronic immunological reactions of this disease 
while Kaehoene et al139  and Palva and Taskinen59 did not support the 
hypothesis of Langerhans cells having a primary role in the development of 
cholesteatoma.58 
Gantz122 hypothesized that the keratin, intracellular debris, and bacteria in 
the retraction pocket of cholesteatomas might be recognized as nonspecific 
antigens by epithelial Langerhans cells, which bound and presented them to 
lymphocytes either in the epithelium or regional lymphnodes, generating a 
cytotoxic T cell response directed at the initial site of sensitization. Even though 
the specific mechanism of activation is unknown, it appears than Langerhans 
cells in cholesteatoma matrix could be an important factor in activating and 
maintaining a chronic inflammatory state in cholesteatomas, resulting in 
connective tissue breakdown and bone resorption. Veldman et all138 found an 
abundant Langerhans cells population not only in the cholesteatoma matrix, but 
also in the subepithelial tissue. In his opinion, this could be the route for the 
mobilized Langerhans cells on their way to the squamous epithelium. Palva and 
Taskinen59 did not agree with Veldman’s systemic concept of cholesteatoma. 
Their observation of Langerhans cells in the secretory epithelioum of subjects 
with secretory otitis media and chronic otitis media, in which there was not the 
slightest sign of keratinisation argued against the specific role for Langerhans 
cells in recurrent cholesteatoma. They felt that Langerhans cells should simply 
be viewed as normal defense cells. In the study done by Park58 there was a 
marked difference in the number and shape of Langerhans cells according to the 
inflammatory condition of the subepithelial tissue of the cholesteama. He found 
that the more the inflammation, the more the number of Langerhans cells. Also 
the Langerhans cells in cholesteatoma matrix with more inflammation had also 
more numerous and longer dendritic processes than those in the normal post 
auricular skin or cholesteatoma matrix with less inflammation. This suggested an 
activated condition of Langerhans cells in the inflamed cholesteatoma matrix. 
Thus, he agreed with the view put forward by Palva and Taskinen59 that 
Langerhans cells may be regarded as normal immune defense cells. However, 
their significant presence at inflammatory sites, suggested that these cells may 
be involved in the proliferation of existing cholesteatoma. 
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4. MATERIALS AND METHODS 
 
4.1. COLLECTION OF SPECIMENS: 
Normal tympanic membranes were collected from cadavers donated to 
the Department of Anatomy, Christian Medical College, Vellore. The cadavers 
chosen for the study died of causes other than ear disease and had no known 
history of chronic ear disease. Collection of specimens was done within 48 hours 
from death. 
Specimens of tympanic membrane were collected from patients 
undergoing tympanoplasty for chronic otitis media of the tubotympanic and 
atticoantral varieties, in the Department of ENT, Christian Medical College, 
Vellore. After acquiring patient consent, the freshened edges of the tympanic 
membrane, removed as a routine part of the surgery and deemed for discard, 
were collected. 
One tympanic membrane collected was from an individual who had a 
traumatic perforation, who underwent a tympanoplasty for the same. 
 
4.2. CALCULATION OF SAMPLE SIZE: 
A morphometric analysis of Langerhans cells in the tympanic membrane 
with regard to number of cells per unit length of basement membrane has not 
been reported prior to this. Hence, a pilot study was carried out comparing one 
normal tympanic membrane with one tympanic membrane with atticoantral 
disease and five tympanic membranes with tubotympanic disease.  
Based on the pilot data, the mean (standard deviation) of number of cells 
per 100µm length of basement membrane was 9.3(3.3) and 3.0(0.89) in the 
tubotympanic disease and normal groups respectively. Using 3.3 as the standard 
deviation for the two groups (normal group had only one sample) with α and β 
errors at 5% and 20% respectively, the sample size needed to be studied was a 
minimum of 6 in each group.  
However, it must also be borne in mind that availability of normal tympanic 
membrane for study is extremely low, as only cadavers donated to the Anatomy 
department within 48 hours of death could be used. Since the number of controls 
is rare, the case- control ratio was divided as 9:1. That means a minimum of 16 
cases and 2 controls were required to attain a total of 18 cases. However, this is 
the minimum number required to be studied.  
The total number of samples collected for study was 60. Of these, only 33 
had adequate epithelium for study. The numbers obtained in each group were: 
Normals: 2 
Tubotympanic disease: 27 
Atticoantral disease: 3 
Traumatic perforation: 1 
 
4.3. FIXATION AND PROCESSING OF TISSUES: 
The collected tissues were fixed in neutral formalin for 1 week. Processing 
of the specimens into paraffin blocks was done as per the standard technique of 
dehydration in ascending grades of isopropyl alcohol, clearing in toluene and 
finally, impregnation and embedding in molten paraffin wax. 
 
4.4. STAINING OF SECTIONS: 
4 micron serial sections were floated onto pre-cleaned slides which were 
coated with poly L-lysine. These were then incubated in a 37° C oven for 24 hrs 
and then a 58° C oven overnight, before they were ready for staining. 
 
4.4.1. Staining with haematoxylin and eosin: 
In each biopsy, sample sections at regular intervals of the serial ribbon 
were selected for staining with haematoxylin and eosin stain as per the standard 
technique. 
 
4.4.2. Immunocytochemal staining (CD1a): 
In each biopsy serial sections in which the epithelium was clearly visible 
by haematoxylin and eosin staining, were selected for immunohistochemical 
staining. The technique used for immunohistochemical staining for CD1a was the 
Polymer-HRP detection system, which is a modification of the standard avidin-
biotin peroxidase technique. However, this is a biotin free detection system. 
The primary antibody used was pre-diluted purified mouse monoclonal 
antibody diluted in phosphate buffered saline, pH 7.6, containing 1% BSA and 
0.09% sodium azide, of the Biogenex Company. 
Also obtained from the Biogenex Company was a super sensitive polymer-
HRP detection kit containing: 
a. Peroxide block: 3% hydrogen peroxide in water 
b. Power block reagent: Casein and propriety additives in PBS with 0.09% 
sodium azide, used as a protein blocking agent. 
c. Super enhancer reagent: A catalyst reagent used to enhance the signal 
after primary antibody incubation. 
d. Poly HRP reagent: Anti-mouse and anti-rabbit IgG, labeled with enzyme 
polymer in phosphate buffered saline. 
e. Liquid DAB chromogen: Diamino benzidine wich is a sensitive HRP 
colorimetric chromogen. 
f. Stable DAB substrate buffer: Tris buffer containing the peroxides and 
stabilizers. 
g. Rabbit negative control and mouse negative control (non immune serum 
in phosphate buffered saline).  
 
Principles of the polymer technique of CD1a staining: 
The demonstration of antigens in tissues and cells by 
immunohistochemical staining is a two-step process involving first, the binding of 
an antibody to the antigen of interest, and second, the detection and visualization 
of the bound antibody by one of a variety of enzyme chromogen systems. The 
advantage of the polymer kit technique over the standard avidin-biotin system is 
that problems associated with endogenous biotin are completely eliminated. 
Preparation of the buffers used: 
EDTA buffer: This was used as the buffer during antigen retrieval. 
For 2 litres of buffer,  
• Tris: 12.1 grams 
• EDTA: 1.493 grams 
• Distilled water: To make up to 2 litres 
The pH of the solution was adjusted to 9.0. 
 
Tris Buffered Saline: This was used as the wash buffer during the staining 
procedure. 
For 2 litres of buffer, 
• Sodium chloride: 16 grams 
• Tris: 1.210 grams 
• 1 Normal Hydrochloric acid: 8 ml 
The pH of the solution was adjusted to 7.6.   
 
Steps of the staining procedure: 
1. The PLL coated slides with the sections of tympanic membrane were 
dewaxed in xylene for 30 minutes.  
2. They were then placed in 2 changes of 1 minute each of absolute 
isopropyl alcohol, to remove the xylene. 
3. Slides were washed in running tap water for 10 minutes. 
4. ANTIGEN RETRIEVAL: The process of fixation of tissue and processing 
into paraffin blocks masks the presence of antigenic epitopes, because of 
the formalin cross-linking that occurs. Thus, prior to immuno-staining, 
paraffin sections require to undergo a process known as antigen retrieval, 
whereby these formalin cross-links are broken and the antigens are free to 
react. Different primary antibodies have different techniques of antigen 
retrieval. The technique of antigen retrieval for the CD1a antigen 
employed involved pressure cooking as per the following steps. 
a. Sections were transferred to distilled water for 1-2 minutes. 
b. EDTA buffer was preheated by steaming in a pressure 
cooker without weight until steam escaped. 
c. The slides were arranged in a slide rack with adequate gap 
and then transferred to preheated buffer. 
d. This was then pressure cooked for 10 minutes at 120° C, 15 
lbs pressure. 
e. The cooker was cooled to room temperature by plunging into 
a sink with water. 
f. The slides were then transferred to distilled water for 5 
minutes. 
g. They were then transferred to Tris Buffered Saline (TBS) for 
2 changes of 5 minutes each. 
The remaining steps of staining were carried out in an air-conditioned 
room. 
 
 
Fig. 1: Slides arranged in EDTA buffer for Antigen retrieval by pressure cooking 
  
 
 
 
 
 
 
Fig. 2: Work table with some of the apparatus used in immunohistochemical 
staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Some equipment used during preparation of the buffers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. PEROXIDASE BLOCK: This was used to block endogenous peroxidases. 
This step was carried out in a dark room to prevent decomposition of the 
hydrogen peroxide. Sections were covered with the peroxidase block 
solution and slides were placed in a humidification chamber for 10- 15 
minutes. 
6. The light was turned back on at this stage. Excess solution was drained 
away and transferred to Tris Buffered Saline for 2 changes of 5 minutes 
each.  
7. POWER BLOCK: This was to block endogenous proteins. Sections were 
covered with the required amount of power block solution and slides 
placed in humidification chamber for 10 minutes.        
8. Excess power block solution was wiped away but there was no TBS wash 
at this step. 
9. PRIMARY ANTIBODY: The sections were covered with required amount 
of pre-diluted primary antibody (CD1a). They were arranged in the 
humidification chamber and left to stand for 1 hour. 
10. Excess antibody was drained away and washed in Tris Buffered Saline 2 
changes, 5 minutes each. 
11. SUPER ENHANCER: This solution acted as a catalyst in the reaction. 
Sections covered with required amount of super enhancer solution and 
placed in humidification chamber for 30 minutes.        
12. Excess solution drained away and washed in Tris Buffered Saline 2 
changes, 5 minutes each. 
13. POLY HRP REAGENT: This is the enzyme labeled antibody solution. 
Sections were covered with required amount of solution and incubated in 
the humidification chamber for 30 minutes.               
14. Excess solution drained was away and the slides were washed in Tris 
Buffered Saline 2 changes, for 5 minutes each. 
15. DIAMINO BENZIDINE: This step was the chromogen reaction to visualize 
the enzyme labeled antigen-antibody complex. Again, it was done in the 
dark to prevent degradation of hydrogen peroxide. 1ml of stable DAB 
buffer was mixed with 1 drop of DAB solution and sections covered with 
required amount of this solution. Slides were placed in humidification 
chamber for 5- 8 minutes.               
16. Excess solution was drained away and washed in Tris Buffered Saline for 
5 minutes. 
17. Slides were washed in running tap water for 10 minutes. 
18. COUNTER STAINING: This was done to achieve a nuclear stain for the 
cells in the sections. 
a. 2 dips in Harris Haematoxyline. 
b. Running water for 5 minutes. 
c. 2 dips in Lithium Carbonate for blueing. 
d. Running Tap water for 5 minutes to enhance blueing further.  
19.  Slides were then blotted, air-dried, dipped in xylem and mounted using 
DPX. 
 
CONTROLS: For each batch of staining done sections of lymph nodes with 
Langerhans cell histiocytosis were used as positive controls. Negative controls 
were not used due to expense of the reagents. 
 
4.5. LIGHT MICROSCOPIC STUDIES: 
 
4.5.1: Slides stained with Eosin and Haematoxyline: 
The sample slides which were stained with eosin and haematoxylin were 
used as guides to identify areas in the biopsy where the stratified squamous 
epithelium of the outer layer of the tympanic membrane was uninterrupted. In the 
normal tympanic membrane, the slides stained were studied to ensure that there 
were no features of acute or chronic inflammation. 
 
4.5.2: Morphometric analysis of Langerhans cells done in the slides stained 
by immunocytochemistry (CD1a): 
In the cases where the tympanic membrane was obtained during 
tympanoplasty surgeries, only the freshened edges from the margins of the 
tympanic membrane perforations were obtained. Thus the total length of 
tympanic membrane obtained in each case was only a few millimeters. 
Therefore, the decision was taken to calculate the number of cells present per 
100µm length of basement membrane. 
Slides were examined under a Leitz DMRHC Research microscope using 
semi-automated image analyzing software, Leica Qwin. 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: Leitz microscope connected to a computer with Leica Qwin  
semi-automated image analysis software used for measurements in this study 
 
 
 
 
 
 
 
 
 
 
 
 
For each sample, 25 fields measuring 100µm were studied under high 
power (40X) magnification.  
The parameters measured were: 
1. The number of CD1a positive cells in which the nucleus was clearly 
visible for 100µm length of basement membrane. 
2. In each specimen the horizontal diameters, measured parallel to the 
basement membrane of the stratified squamous epithelium, and the 
vertical diameters, measured perpendicular to it, of 10 cells were 
measured. Also measured in these cells were the number of dendritic 
processes and the length of each dendritic process. 
 
4.6. ANALYSIS: 
 
4.6.1: Qualitative Analysis: 
The slides were studied to appreciate the morphology and pattern of 
distribution in the epithelium and subepithelial connective tissue and the 
interesting findings were described. 
 
4.6.2: Statistical Analysis: 
The mean number of cells per 100µm length of basement membrane was 
calculated in each of the 4 groups and these were compared using Kruskal 
Wallis test.  
The mean diameter of each cell was calculated as the average of the 
horizontal and vertical diameters of the cell, horizontal diameter measured 
parallel to the basement membrane of the epithelium and vertical diameter 
measured perpendicular to it.  Also studied, were the mean length of the dendritic 
processes and the mean number of processes per cell in each group.  
The mean number of cells per 100µm length of basement membrane, the 
mean diameter of each cell, the mean length of dendritic processes and the 
mean number of dendritic processes per cell were compared between 2 groups 
by the non-parametric, Mann-Whitney U test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
5. RESULTS 
 
5.1. QUALITATIVE ANALYSIS: 
 
5.1.1. Sections stained with haematoxylin and eosin: 
  
 Out of the 60 samples that were processed for light microscopy it was 
found after staining with haematoxylin and eosin, that only 33 of these had 
adequate epithelium to be studied.  
 The normal cadaveric biopsies were examined and it was confirmed that 
there were no signs of acute or chronic inflammation. 
 In the tympanic membranes from cadavers with chronic otitis media of the 
tubotympanic variety, the epithelium was markedly thickened, with 
hyperkeratosis and rete pegs. There was moderately dense diffuse chronic 
inflammation which was lympho-plasmacytic in nature. There were variable 
degrees of fibrosis in the biopsies. Fig.5 shows a tympanic membrane of a 
patient with tubotympanic disease showing the layers of the tympanic membrane. 
 Similar inflammatory cells were seen in the biopsies with chronic otitis 
media of the atticoantral variety. However the epithelium was markedly hyper-
keratotic and the granular layer was very prominent. Also, in these biopsies, the 
inflammation appeared focal and perivascular nature. 
 
 
 
 
 
 
 
 
 
Fig.5: A biopsy of tympanic membrane from a patient with tubotympanic disease, 
stained with haematoxylin and eosin, viewed under low power. Note the 
hyperkeratosis, markedly thickened cuticular layer, chronic inflammatory cells 
and fibrosis  
 
 
 
 
 
 
 
 
 
 
 
 
  The biopsy of the tympanic membrane with the traumatic perforation 
looked remarkably like the normal tympanic membrane biopsies, without signs of 
lymphocytic infiltration. 
 
5.1.2. Sections stained by immunohistochemical technique: 
  
 All the 33 biopsies studied contained CD1a positive cells. The four 
categories looked at were normal tympanic membrane, tympanic membrane in 
tubotympanic disease, tympanic membrane in atticoantral disease and tympanic 
membrane after traumatic perforation. 
 The structure of the Langerhans cells seen was similar to those described 
in previous studies involving these cells. The cell body was round to ovoid with a 
large circular nucleus. From the cell body arose 1 to 6 dendritic processes. 
Several of these dendritic processes branched further, forming a highly 
interconnected network of processes. Many of these terminal processes ended in 
contact with the processes of other dendritic cells, showing the vast 
intercommunication between these cells (Fig. 6).  
In the tympanic membranes studied, a variety of Langerhans cells were 
seen. In some areas, the dendritic processes were seen to be directed towards 
the surface of the stratified squamous epithelium in a manner similar to that 
described by Takahashi and Nakano73. However, this was not a uniform feature 
in the biopsies with cholesteatoma, as some processes appeared to be directed  
 
 
 
 
 
 
 
 
 
 
Fig. 6: Tympanic membrane stained with CD1a antibody, counter-stained with 
Harris Haematoxylin, viewed under oil immersion. 
 Note the branching dendritic processes which intercommunicate with each other.  
 
 
 
 
 
 
 
 
 
 
 
 
towards other Langerhans cells and lymphocytes as well. Moreover, this 
feature was also seen in the biopsies with tubotympanic disease (Fig. 7 and 8). 
Langerhans cells seen in the tympanic membrane were found to fall into 
similar groups to those described by Figueroa and Caorsi,62 who conducted an 
ultrastructural and morphometric study of the Langerhans cells in the normal 
human exocervix. According to their classification, Langerhans cells could be 
dividied into 5 groups based on the number of dendritic processes they contained 
and the pattern of branching of these dendritic processes, as described below. 
• Type I cells had a single, unbranched process (Fig. 9).  
• Type II cells had a single process which in turn was branched (Fig. 9, 10 
and 13).  
• Type III cells were cells with 2 processes, irrespective of their branching 
pattern (Fig. 11, 12 and 13).  
• Type IV cells had 3 or more dendritic processes (Fig. 14 and 15).  
• Type V cells also had 3 or more processes, but these in turn branched 
intricately. (Fig. 16 and 17). 
 
Another feature noticed was that although the CD1a positive Langerhans 
cells were mainly concentrated in the stratified squamous epithelial layer of the 
tympanic membrane, migration of these cells was noticed into the subepithelial 
connective tissue. Also, in the subepithelium, these cells were seen in close 
relation with aggregations of lymphocytes (Fig. 18, 19 and 20). 
 
 
 
Figures 7 and 8: Tympanic membrane stained with CD1a antibody, counter-
stained with Harris Haematoxylin. Note the processes directed towards the 
surface of the stratified squamous epithelium. 
 
Fig. 7: viewed under oil immersion. 
 
 
 
 
Fig. 8: viewed under oil immersion. 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Tympanic membrane stained with CD1a antibody, counter-stained with 
Harris Haematoxylin. Magnification: 833 
A type I cell with a single long unbranched process is seen along with a type II 
cell with a single process which divides into branches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: Tympanic membrane stained with CD1a antibody, counter-stained with 
Harris Haematoxylin. More type II cells with single, branching processes are 
seen 
 
Viewed under oil immersion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 11 and 12: Tympanic membrane stained with CD1a antibody, counter-
stained with Harris Haematoxylin. Type III cells, each having two dendritic 
processes are seen. 
 
Fig. 11: Magnification: 667 
 
 
Fig. 12: Viewed under oil immersion 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Tympanic membrane stained with CD1a antibody, counter-stained with 
Harris Haematoxylin, viewed under oil immersion. Type II and type III cells are 
seen. 
 
Magnification: 1100 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 14 and 15: Tympanic membrane stained with CD1a antibody, counter-
stained with Harris Haematoxylin, viewed under high power 
Type IV cells with 3 or more processes seen.  
 
 
Fig. 14: Magnification: 367 
 
 
 
Fig .15: Magnification: 438 
 
 
 
 
 
 
Figures 16 and 17: Tympanic membrane stained with CD1a antibody, counter-
stained with Harris Haematoxylin. Type V cells with 3 or more processes which 
further arborise seen. 
 
Fig. 16: Viewed under oil immersion 
 
 
 
Fig. 17: Viewed under oil immersion 
 
 
anic membrane stained with CD1a antibody, counter-stained with Harris 
Haematoxylin. Note the serial sections showing migration of the cells into the 
subepithelium and association with lymphoid aggregates 
 
 
Fig. 18: Magnification: 133 
 
 
 
Fig. 19: Magnification: 225 
 
 
 
Fig. 20: Magnification:150 
 
 
Interestingly, contrary to studies described earlier, the biopsies of the 
normal tympanic membranes studied contained CD1a positive Langerhans cells 
in their entire length. The cells appeared to be smaller and fewer in number than 
those with chronic otitis media.  
Of the biopsies with chronic otitis media, those with atticoantral disease 
appeared to have more Langerhans cells than those with tubotympanic disease. 
These numbers were quantified and the data is presented in the tables that 
follow in the section on the statistical analysis. The following series of pictures 
shows the distribution of CD1a positive Langerhans cells in the tympanic 
membrane in the above conditions. (Fig. 21, 22 and 23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21: Normal tympanic membrane stained with CD1a antibody, counter-
stained with Harris Haematoxylin, viewed under low power. Note the sparse but 
uniform distribution of Langerhans cells. 
 
 
Fig. 22: Tympanic membrane in tubotympanic disease, stained with CD1a 
antibody, counter-stained with Harris Haematoxylin, viewed under low power. 
Note the increase in density of Langerhans cells when compared with the 
previous figure. Magnification: 183 
 
 
 
 
 
 
 
 
 
 
Fig. 23: Tympanic membrane in atticoantral disease, stained with CD1a antibody, 
counter-stained with Harris Haematoxylin. Magnification: 231. Note the obvious 
increase in density of Langerhans cells when compared to figures 21 and 22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2. STATISTICAL ANALYSIS: 
 The four categories looked at were normal tympanic membrane, tympanic 
membrane in tubotympanic disease, tympanic membrane in atticoantral disease 
and tympanic membrane after traumatic perforation. 
 Among the four groups, number of cells per 100µm length of basement 
membrane, diameter of the cells, length of the processes and number of 
processes were studied. 
 
Table 1 
 
Number of cells per 100µm length of basement membrane: 
 
 
 
As is evident from Table 1 and Graph 1, the mean number of Langerhans 
cells seen per 100µm length of basement membrane was lowest in the normal 
tympanic membranes and highest in the atticoantral variety of chronic otitis 
media. 
 
 
Categories Mean number Median Standard deviation 
Normal 3.02 3.00 1.000 
Tubotympanic disease 8.30 8.00 3.519 
Atticoantral disease 17.07 18.00 2.637 
Traumatic perforation 3.20 4.00 1.780 
 
 
 
 
Graph 1 
 
 
UMean number of CD1a positive cells per 100µm length of 
basement membrane 
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The mean number of cells per unit length of basement membrane when 
compared among the four groups, was found to be significantly different from 
each other by the Kruskal Wallis test (p<0.001).  
On comparing pairs of groups by the Mann Whitney U test, it was found 
that the mean (SD) of number of cells in tympanic membranes with tubotympanic 
disease, 8.3(3.5), was significantly higher than the mean (SD) of number of 
cells in the normal tympanic membrane, 3.02(1), (p<0.001). 
Similarly, the mean (SD) of number of cells in tympanic membranes with 
atticoantral disease, 17.07(2.6) was significantly higher than the mean (SD) of 
number of cells in the normal tympanic membrane, 3.02(1), (p<0.001). 
Interestingly, the difference between the mean number of cells in 
membranes with atticoantral disease, 17.07(2.6), was also significantly higher 
than those with tubotympanic disease, 8.3(3.5), (p<0.001). 
It was also seen that there was no evidence of significance when the 
mean number of cells in the normal tympanic membranes were compared with 
that of the traumatic perforation (p= 0.554). 
Inference: From these results, it can be inferred that there is a significant 
increase in the number of Langerhans cells in the cuticular layer of the tympanic 
membrane in chronic otits media of both tubotympanic and atticoantral disease. 
Also, the increase in atticoantral disease is significantly more than that of 
tubotympanic disease. However, in traumatic perforation of the tympanic 
membrane, there is no significant difference in the mean number of Langerhans 
cells. 
 
Mean diameter of the cells 
 
 
The mean diameter of each cell was calculated as the average of the 
horizontal and vertical diameters of the cell, horizontal diameter measured 
parallel to the basement membrane of the epithelium and vertical diameter 
measured perpendicular to it. 
The range of diameters varied from 0.88µm to 3.50µm. This was important 
to know as the thickness of each section studied was 4µm. Thus it can assumed, 
that the body of a particular cell was measured only in one section and would not 
appear in the next. 
 
Table 2 
Diameter of cells 
Categories Mean (µm) Median (µm) Standard deviation 
Normal 1.6962 1.6400 0.36421 
Tubotympanic disease 1.6741 1.65000 0.32071 
Atticoantral disease 2.0327 1.9800 0.51037 
Traumatic perforation 1.7745 1.6700 0.34132 
 
 
Table 2 and Graph 2 indicate that the mean diameter was highest in the 
tympanic membranes with atticoantral disease and lowest in those with 
tubotympanic disease. 
 
 
 
 
 
 
 
Graph 2 
 
 
UMean diameter of CD1a positive cells  
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The mean (SD) diameter of cells in tympanic membranes with atticoantral 
disease, 2.03(0.5) was significantly higher than that of the normal tympanic 
membranes, 1.7(0.36), (p value= 0.014).  
The mean (SD) diameter of cells in tympanic membranes with atticoantral 
disease, 2.03(0.5) was significantly higher than that of tubotympanic disease, 
1.67 (0.32), (p value<0.001). 
Interestingly, the difference in diameters between normal tympanic 
membrane and tubotympanic disease was not found to be statistically 
significant (p value= 0.926) and neither was the difference between normal 
tympanic membrane and that with traumatic perforation (p value= 0.559). 
Inference: From the above results it can be inferred that there is a 
significant increase in the diameter of cells in atticoantral disease, but not in 
tubotympanic disease. 
 
Number and length of dendritic processes 
The number of processes varied from 1 to 6. For each cell, the mean 
length of dendritic processes was also calculated. The mean length of processes 
varied from 0.10µm to 2.67µm. However when the length of each process was 
looked at individually, the longest process measured was found to be 6.2µm. 
This has great significance in the interpretation of this set of results, as the 
thickness of the sections studied was only 4µm each. Thus, it is very likely that 
many of the processes measured, extended from one section to the next and 
hence, the entire length of every process was not measured. 
Table 3 
Length of dendritic processes 
Category Mean length (µm) Median (µm) Standard deviation
Normal 0.8815 0.7367 0.47732 
Tubotympanic disease 0.8042 0.7208 0.44597 
Atticoantral disease 0.8376 0.7417 0.55917 
Traumatic perforation 1.0208 0.9200 0.41011 
 
Table 3 and Graph 3 demonstrate the mean length of dendritic processes 
in each category. There was no evidence of statistical significance seen in the 
mean length of processes between the groups.  
 
Table 4 
Number of dendritic processes 
Category Mean number Median Standard deviation 
Normal 2.8500 3.00 0.93330 
Tubotympanic disease 2.6308 3.00 1.07365 
Atticoantral disease 2.4828 2.00 0.94946 
Traumatic perforation 3.0000 3.00 0.66667 
 
Table 4 and Graph 4 show the mean number of processes in each group 
studied. There was no evidence of significance between the 4 groups. 
 
 
 
 
 
 
 
 
 
 
Graph 3 
 
 
UMean length of dendritic processes 
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Graph 4 
 
 
Mean number of dendritic processes 
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DISCUSSION 
 
 
 
 
 
 
 
 
 
 
6. DISCUSSION 
 The Langerhans cell is part of an extremely dynamic population of 
dendritic cells that possess the ability to traffic tissues and migrate within the 
tympanic membrane. They appear to recognize antigens and present them to T 
lymphocytes, and possibly macrophages. 
 Langerhans cells have previously been described in the tympanic 
membranes of patients with chronic otitis media138-140 and in the matrix of 
cholesteatomas.40, 73, 134-137 However, the presence and distribution of these cells 
in the normal tympanic membrane are controversial. Also, although it has been 
postulated that these cells play a role in the pathogenesis of chronic otitis 
media,40, 58, 59, 73, 134, 138,  specifically of cholesteatoma, a quantification of the 
increase in the number of these cells in these conditions has not been attempted. 
 This is the first study that quantifies the distribution of Langerhans cells in 
the normal tympanic membrane, and quantifies their increase in the tympanic 
membrane in chronic otitis media of the tubotympanic and atticoantral varieties. 
A number of techniques have been described for the identification of 
Langerhans cells by light microscopy. 31, 59, 69-74 These techniques present 
problems with the specificity of reaction and complication of procedure. Of these, 
the tests for cell surface markers are most useful. Studies by Palva and 
Taskinen59 and Harrist et al80 showed that CD1a is a better marker for 
Langerhans cells than others, with regard to sensitivity and specificity for the cell. 
A positive staining reaction with CD1a (also called OKT6/Leu6) is considered by 
some as the gold standard for Langerhans cell identification, despite the fact 
that this epitope is also present in the cortical thymocyte because, with 
maturation, cortical thymocytes lose CD1a before exiting the thymus.45, 88 Thus 
for this study, staining for the cell surface antigen CD1a, was employed. 
The immunological role of the Langerhans cell is now undisputed. Also, 
their increase60,88, 106-111 and decrease112-119 in number in various disease 
conditions have been previously noted. This study looks to quantify their increase 
in the tympanic membrane in chronic otitis media. 
The first part of this study was to verify the presence of these cells in the 
normal tympanic membrane. Looking at previous work done on the normal 
tympanic membrane, some important questions may be raised. Veldman40 stated 
that the normal tympanic membrane was probably devoid of Langerhans cells. 
Hussl et al37 and Gantz122 performed studies on the normal human tympanic 
membrane and these studies had contrasting findings.  
Hussl et al37 looked a cadaveric tympanic membranes from patients who 
had died of causes other than ear disease and had had no history of middle ear 
diseases, removed 14-21 hours after death. He found cells in the epidermal layer 
of the tympanic membrane which were HLA-DR antigen positive but negative for 
CD1a. However, he did not quantify the distribution of these cells. The 
explanation given for this was that possibly cell surface antigens like CD1a 
disintegrate postmortem. 
In the present study however, CD1a positive Langerhans cells are seen in 
both biopsies of normal tympanic membrane studied. Both these membrane 
were collected between 24 and 48 hours postmortem.   
Ichimiya et al133 studied normal tympanic membrane in mice. He found 
that CD1a positive cells were absent in the normal tympanic membrane except in 
the pars flaccida, and in the manubrial and annular parts of the pars tensa. The 
rest of the pars tensa was devoid of Langerhans cells. Gantz122 looked at 
epidermal Langerhans cells in cholesteatoma matrix and compared them with 
normal tympanic membrane and normal ear canal skin. He felt that the cells were 
present in the normal tympanic membrane, although in lower numbers than in the 
cholesteatoma matrix. His finding was that Langerhans cells were evenly 
distributed through the entire surface of the tympanic membrane and not limited 
to the pars flaccida and the annular and manubrial regions of the pars tensa 
In our study, we agree with the findings of Gantz122 that the pars tensa of 
the human tympanic membrane uniformly shows the presence of CD1a positive 
Langerhans cells and not with those of Ichimiya et al133 who stated that the 
Langerhans cells were limited to the pars flaccida and in the manubrial and 
annular parts of the pars tensa. Gantz, however, failed to quantify the distribution 
of cells in order to establish their increase in chronic otitis media. Our study, on 
the other hand proceeds to do that. 
The unavailability of fresh tympanic membrane tissue makes studies on 
the normal tympanic membrane difficult. The normal tympanic membrane is 
almost never removed as a routine part of surgical procedures. Therefore, the 
only means of collection of the tissue was from freshly donated cadavers to the 
Department of Anatomy, donation being done within 48 hours of death. Only 2 
such biopsies could be obtained. This low number of normal tympanic 
membranes studied is a draw back in this study. 
Most investigators of Langerhans cells in chronic otitis media studied 
either the middle ear mucosa138-140 in these conditions or the matrix of the 
cholesteatoma in atticoantral disease. 40, 73, 134-137 This study, however, compares 
numbers of Langerhans cells in the tympanic membrane in these conditions. It 
was found that there is a statistically significant increase in the number of 
Langerhans cells in chronic otitis media of both the tubotympanic and atticoantral 
varieties when compared with the normal tympanic membrane. Interestingly, the 
difference between the mean number of cells in tubotympanic and atticoantral 
disease was also statistically significant. These findings support the theory of 
Veldman40 and van Dijk et al138 that these cells have an important role in the 
pathogenesis of these diseases. 
Sections show these cells concentrated within the stratified squamous 
epithelium but also in the subepithelial connective tissue and in close conjunction 
with lymphoid aggregates. This supports the migratory role of these Langerhans 
cells.  
Langerhans calls have been known to control the lymphoid cell traffic.59 
Our frequent finding of these cells in the subepithelial follicles is in accordance 
with this function. 
Park58 reported that the matrix of cholesteatoma had Langerhans cells 
whose processes were longer and more branched. However, her did not report 
an increase in cell diameter. An interesting finding of this study is that the mean 
diameter of cells is increased significantly in the tympanic membranes of cases 
with atticoantral disease when compared with the normal tympanic membranes. 
This increase in cell size is probably a result of their immunological activation in 
the presence of antigen. However, the cell diameter does not significantly 
increase in tubotympanic disease. 
Veldman et al,138 Gantz122 and Takahashi and Nakano,73 all suggested 
that Langerhans cells within the cholesteatoma matrix were responsible for 
generating and maintaining the chronic immunological reactions of this disease. 
However, Kaehoene et al139 and Palva and Taskinen59 did not support this 
hypothesis. They felt that the presence of Langerhans cells in the secretory 
epithelium of subjects with secretory otitis media and chronic otitis media, in 
which there was not the slightest sign of keratinisation argued against the 
specific role for Langerhans cells in recurrent cholesteatoma. They felt that 
Langerhans cells should simply be viewed as normal defense cells.  
Our finding of significant increase in the number of Langerhans cells in the 
tubotympanic variety of chronic otitis media is in favour of the latter theory. 
However, their significant increase in chronic otitis media of atticoantral variety 
suggests that these cells may be involved in the proliferation of existing 
cholesteatoma. 
Contrary to the observation made by Park58 that Langerhans cells found in 
the matrix of cholesteatoma had longer and increased number of dendritic 
processes, we found that the difference in the number and length of dendritic 
processes between the groups was not statistically significant. One possible 
explanation could be that adequate samples of atticoantral disease and normal 
tympanic membrane were not studied. The other possibility is that this increase 
in number of processes and arborisation occurs only in the cholesteatoma matrix 
and not in the tympanic membrane. 
Takahashi and Nakano73 reported that in the cholesteatomatous tissue, 
dendritic processes were mainly directed towards the surface of the epithelium. 
In the present study, although this was noted in some areas, it was not a 
universal feature. This can be explained by the fact that the processes inter-
communicate greatly with those of other dendritic cells, passing on antigenic 
information between them and also with lymphocytes. 
One of the diseased biopsies obtained was from the margins of a 
traumatic perforation of the tympanic membrane. When the cells properties and 
distribution in this specimen was compared with the other groups, it was seen 
that there was no significant difference in the number of cells per unit length of 
basement membrane, diameter of cells, length of processes and number of 
processes between this biopsy and the normal tympanic membrane. This 
supports the role of the Langerhans cell in antigen presentation as this biopsy 
was devoid of infection. 
 
Clinical Relevance: 
Interference with Langerhans cell-Tcell function is a goal of future 
research. Inactivation of cell receptors or removal of Langerhans cells from the 
skin is probably the key to influencing the clinical behaviour of various skin 
related diseases including cholesteatoma. 
Through immunopathologic evaluation, the clinical aggressiveness of a 
cholesteatoma could become predictable, having consequences for the future 
handling of cholesteatomas. 
The knowledge of the role of Langerhans cells in the pathogenesis of 
cholesteatoma is especially relevant, as medical manipulation of Langerhans 
cells could be used as an adjuvant to surgery in the future handling of 
cholesteatomas. 
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7. CONCLUSIONS 
 
1. The normal tympanic membrane does contain Langerhans cells 
distributed through the pars tensa. 
 
2. The mean number of Langerhans cells per unit length of basement 
membrane in chronic otitis media of the tubotympanic variety is 
significantly higher than that of the normal tympanic membrane. 
 
3. The mean number of Langerhans cells per unit length of basement 
membrane in chronic otitis media of the atticoantral variety is significantly 
higher than that of the normal tympanic membrane and chronic otitis 
media of the tubotympanic variety. 
 
4. In chronic otitis media of the atticoantral variety, the mean diameter of the 
cells increases significantly. 
 
5. The mean number of dendritic processes and their length do not increase 
significantly in chronic otitis media. 
 
 
 
 
  
 
 
 
REFERENCES 
 
 
 
 
 
REFERENCES (Arranged in chronological order) 
 
1. The anatomy of the immune response. In: Delves PJ, Martin SJ, Burton 
DR, Roitt IM, Editors. Roitt’s essential immunology. 11th ed. Australia: 
Blackwell Publishing; 2006. p. 155-70. 
 
2. Romani N, Schuler G. The immunologic properties of epidermal 
Langerhans cells as a part of the dendritic cell system. Springer Semin 
Immunopathol. 1992;13(3-4):265-79. 
 
3. Stiles DP, Terr AI, Parslow TG, Editors. Basic and clinical immunology. 8th 
ed. Norwalk (CT): Appleton and Lange; 1994. p. 63-4 
 
4. Steinman RM. The dendritic cell system and its role in immunogenicity. 
Annu Rev Immunol. 1991;9:271-96. 
 
5. Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis 
contain dendritic cells. Isolation by means of a novel method and 
phenotypical and functional characterization. J Clin Invest. 1993 
Dec;92(6):2587-96. 
 
6. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. 
Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811. 
 
7. Young JW, Steinman RM. The hematopoietic development of dendritic 
cells: a distinct pathway for myeloid differentiation. Stem Cells. 1996 
Jul;14(4):376-87. 
 
8. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into 
potent immunostimulatory dendritic cells in vitro. J Exp Med. 1985 Mar 
1;161(3):526-46. 
 
9. Holt PG, Schon-Hegrad MA, Oliver J. MHC class II antigen-bearing 
dendritic cells in pulmonary tissues of the rat. Regulation of antigen 
presentation activity by endogenous macrophage populations. J Exp Med. 
1988 Feb 1;167(2):262-74. 
 
10. Sertl K, Takemura T, Tschachler E, Ferrans VJ, Kaliner MA, Shevach EM. 
Dendritic cells with antigen-presenting capability reside in airway 
epithelium, lung parenchyma, and visceral pleura. J Exp Med. 1986 Feb 
1;163(2):436-51. 
 
11. Holt PG, Schon-Hegrad MA, McMenamin PG. Dendritic cells in the 
respiratory tract. Int Rev Immunol. 1990;6(2-3):139-49. 
 
12. Pavli P, Woodhams CE, Doe WF, Hume DA. Isolation and 
characterization of antigen-presenting dendritic cells from the mouse 
intestinal lamina propria. Immunology. 1990 May;70(1):40-7. 
 
13. Liu LM, MacPherson GG. Antigen acquisition by dendritic cells: intestinal 
dendritic cells acquire antigen administered orally and can prime naive T 
cells in vivo. J Exp Med. 1993 May 1;177(5):1299-307. 
 
14. Hart DN, Fabre JW. Demonstration and characterization of Ia-positive 
dendritic cells in the interstitial connective tissues of rat heart and other 
tissues, but not brain. J Exp Med. 1981 Aug 1;154(2):347-61. 
 
15. Klinkert WE, LaBadie JH, Bowers WE. Accessory and stimulating 
properties of dendritic cells and macrophages isolated from various rat 
tissues. J Exp Med. 1982 Jul 1;156(1):1-19. 
 
16. Pugh CW, MacPherson GG, Steer HW. Characterization of nonlymphoid 
cells derived from rat peripheral lymph. J Exp Med. 1983 Jun 
1;157(6):1758-79. 
 
17. Fossum S. Lymph-borne dendritic leucocytes do not recirculate, but enter 
the lymph node paracortex to become interdigitating cells. Scand J 
Immunol. 1988 Jan;27(1):97-105. 
 
18. O'Doherty U, Steinman RM, Peng M, Cameron PU, Gezelter S, Kopeloff I, 
et al. Dendritic cells freshly isolated from human blood express CD4 and 
mature into typical immunostimulatory dendritic cells after culture in 
monocyte-conditioned medium. J Exp Med. 1993 Sep 1;178(3):1067-76. 
 
19. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, et 
al. Human blood contains two subsets of dendritic cells, one 
immunologically mature and the other immature. Immunology. 1994 
Jul;82(3):487-93. 
 
20. Austyn JM, Kupiec-Weglinski JW, Hankins DF, Morris PJ. Migration 
patterns of dendritic cells in the mouse. Homing to T cell-dependent areas 
of spleen, and binding within marginal zone. J Exp Med. 1988 Feb 
1;167(2):646-51. 
 
21. Kaplan G, Nusrat A, Witmer MD, Nath I, Cohn ZA. Distribution and 
turnover of Langerhans cells during delayed immune responses in human 
skin. J Exp Med. 1987 Mar 1;165(3):763-76. 
 
22. Matzinger P, Guerder S. Does T-cell tolerance require a dedicated 
antigen-presenting cell? Nature. 1989 Mar 2;338(6210):74-6. 
 
23. Zal T, Volkmann A, Stockinger B. Mechanisms of tolerance induction in 
major histocompatibility complex class II-restricted T cells specific for a 
blood-borne self-antigen. J Exp Med. 1994 Dec 1;180(6):2089-99. 
 
24. Lindhout E, de Groot C. Follicular dendritic cells and apoptosis: life and 
death in the germinal centre. Histochem J. 1995 Mar;27(3):167-83. 
25. Rabi S, Indrasingh I, Koshy S. Distribution of Zinc Iodide-osmium positive 
dendritic cells in the human appendix. Eur J Anat. 2006;10(1):15-20. 
 
26. Tew JG, Thorbecke GJ, Steinman RM. Dendritic cells in the immune 
response: characteristics and recommended nomenclature (A report from 
the Reticuloendothelial Society Committee on Nomenclature). J 
Reticuloendothel Soc. 1982 May;31(5):371-80. 
 
27. Yamada K, Yamakawa M, Imai Y, Tsukamoto M. Expression of cytokine 
receptors on follicular dendritic cells. Blood. 1997 Dec 15;90(12):4832-41. 
 
28. Haines KA, Flotte TJ, Springer TA, Gigli I, Thorbecke GJ. Staining of 
Langerhans cells with monoclonal antibodies to macrophages and 
lymphoid cells. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3448-51. 
 
29. Barclay AN. Different reticular elements in rat lymphoid tissue identified by 
localization of Ia, Thy-1 and MRC OX 2 antigens. Immunology. 1981 
Dec;44(4):727-36. 
 
30. Thorbecke GJ, Silberberg-Sinakin I, Flotte TJ. Langerhans cells as 
macrophages in skin and lymphoid organs. J Invest Dermatol. 1980 
Jul;75(1):32-43. 
 
31. Langerhans P. Ueber die Nerven der menschlichen llaut. Virchows Arch 
(Pathol Anat) 1868;44:325-37. 
 
32. Jolles S. Paul Langerhans. J Clin Pathol. 2002 Apr;55(4):243. 
 
33. Silvers WK. A histological and experimental approach to determine the 
relationship between gold-impregnated dendritic cells and melanocytes. 
Am J Anat. 1957 Mar;100(2):225-39. 
 
34. Chu A, Eisinger M, Lee JS, Takezaki S, Kung PC, Edelson RL. 
Immunoelectron microscopic identification of Langerhans cells using a 
new antigenic marker. J Invest Dermatol. 1982 Feb;78(2):177-80. 
 
35. Birbeck M, Breathnach A, Everall J. An electron microscopic study of 
basal melanocytes and high level clear cells (lagerhans cells) in vitiligo. J 
Invest Dermatol. 1961;37:51. 
 
36. Silberberg I. Apposition of mononuclear cells to langerhans cells in contact 
allergic reactions. An ultrastructural study. Acta Derm Venereol. 
1973;53(1):1-12. 
 
37. Hussl B, Egg G, Romani N, Kong W, Schrott-Fischer A. Dendritic cells in 
the normal human tympanic membrane. Ann Otol Rhinol Laryngol. 1995 
Oct;104(10 Pt 1):803-7. 
 
38. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived 
from cells originating in bone marrow. Nature. 1979 Nov 
15;282(5736):324-6. 
 
39. Stingl G, Tamaki K, Katz SI. Origin and function of epidermal Langerhans 
cells. Immunol Rev. 1980;53:149-74. 
 
40. Veldman JE. Immunology of cholesteatoma. Am J Otol. 1985 Jan;6(1):22-
5. 
 
41. Barclay AN. Different reticular elements in rat lymphoid tissue identified by 
localization of Ia, Thy-1 and MRC OX 2 antigens. Immunology. 1981 
Dec;44(4):727-36. 
 
42. Stingl G, Wolff-Schreiner EC, Pichler WJ, Gschnait F, Knapp W, Wolff K. 
Epidermal Langerhans cells bear Fc and C3 receptors. Nature. 1977 Jul 
21;268(5617):245-6. 
 
43. Klareskog L, Tjernlund U, Forsum U, Peterson PA. Epidermal Langerhans 
cells express Ia antigens. Nature. 1977 Jul 21;268(5617):248-50. 
 
44. Rowden G, Lewis MG, Sullivan AK. Ia antigen expression on human 
epidermal Langerhans cells. Nature. 1977 Jul 21;268(5617):247-8. 
 
45. Toews GB, Bergstresser PR, Streilein JW. Langerhans cells: sentinels of 
skin associated lymphoid tissue. J Invest Dermatol. 1980 Jul;75(1):78-82. 
 
46. Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, Enjyoji K, et 
al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: 
modulatory roles in inflammation and immune responsiveness. Nat Med. 
2002 Apr;8(4):358-65. 
 
47. Streilein JW, Bergstresser PR. Langerhans cells: antigen presenting cells 
of the epidermis. Immunobiology. 1984 Dec;168(3-5):285-300. 
 
48. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. 
Langerhans cells renew in the skin throughout life under steady-state 
conditions. Nat Immunol. 2002 Dec;3(12):1135-41. 
49. Stingl G, Katz SI, Clement L, Green I, Shevach EM. Immunologic 
functions of Ia-bearing epidermal Langerhans cells. J Immunol. 1978 
Nov;121(5):2005-13. 
 
50. Silberberg-Sinakin I, Gigli I, Baer RL, Thorbecke GJ. Langerhans cells: 
role in contact hypersensitivity and relationship to lymphoid dendritic cells 
and to macrophages. Immunol Rev. 1980;53:203-32. 
 
51. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, et al. 
Langerhans cells utilize CD1a and langerin to efficiently present 
nonpeptide antigens to T cells. J Clin Invest. 2004 Mar;113(5):701-8. 
52. Silberberg-Sinakin I, Thorbecke GJ. Contact hypersensitivity and 
Langerhans cells. J Invest Dermatol. 1980 Jul;75(1):61-7. 
 
53. Stingl G. New aspects of Langerhans' cell function. Int J Dermatol. 1980 
May;19(4):189-213. 
 
54. Silberberg-Sinakin I, Baer RL, Thorbecke GJ. Langerhans cells: a review 
of their nature with emphasis on their immunologic functions. Prog Allergy. 
1978;24:268-94. 
 
55. Silberberg-Sinakin I, Fedorko ME, Baer RL, Rosenthal SA, Berezowsky V, 
Thorbecke GJ. Langerhans cells: target cells in immune complex 
reactions. Cell Immunol. 1977 Aug;32(2):400-16. 
 
56. Kripke ML, Munn CG, Jeevan A, Tang JM, Bucana C. Evidence that 
cutaneous antigen-presenting cells migrate to regional lymph nodes 
during contact sensitization. J Immunol. 1990 Nov 1;145(9):2833-8. 
 
57. Cumberbatch M, Kimber I. Dermal tumour necrosis factor-alpha induces 
dendritic cell migration to draining lymph nodes, and possibly provides one 
stimulus for Langerhans' cell migration. Immunology. 1992 Feb;75(2):257-
63. 
 
58. Park K. Significance of Langerhans' cells in middle ear cholesteatoma. 
Yonsei Med J. 1994 Dec;35(4):438-45. 
 
59. Palva T, Taskinen E. Inflammatory cell subpopulations in chronic otitis 
media. The Langerhans' cells. Arch Otolaryngol Head Neck Surg. 1987 
Feb;113(2):149-54. 
 
60. Shelley WB, Juhlin L. Langerhans cells form a reticuloepithelial trap for 
external contact antigens. Nature. 1976 May 6;261(5555):46-7. 
 
61. Wolff K. The langerhans cell. Curr Probl Dermatol. 1972;4:79-145. 
 
62. Figueroa CD, Caorsi I. Ultrastructural and morphometric study of the 
Langerhans cell in the normal human exocervix. J Anat. 1980 Dec;131(Pt 
4):669-82. 
 
63. Wolff K. The fine structure of the Langerhans cell granule. J Cell Biol. 
1967 Nov;35(2):468-73. 
 
64. Mc Dermott R, Ziylan U, Spehner D, Bausinger H, Lipsker D, Mommaas 
M, et al. Birbeck granules are subdomains of endosomal recycling 
compartment in human epidermal Langerhans cells, which form where 
Langerin accumulates. Mol Biol Cell. 2002 Jan;13(1):317-35. 
 
65. Hanau D, Fabre M, Schmitt DA, Stampf JL, Garaud JC, Bieber T, et al. 
Human epidermal Langerhans cells internalize by receptor-mediated 
endocytosis T6 (CD1 "NA1/34") surface antigen. Birbeck granules are 
involved in the intracellular traffic of the T6 antigen. J Invest Dermatol. 
1987 Aug;89(2):172-7. 
 
66. Zelickson AS. Granule formation in the Langerhans cell. J Invest 
Dermatol. 1966 Nov;47(5):498-502. 
 
67. Bartosik J. Cytomembrane-derived Birbeck granules transport horseradish 
peroxidase to the endosomal compartment in the human Langerhans 
cells. J Invest Dermatol. 1992 Jul;99(1):53-8. 
 
68. Ishii M, Terao Y, Kitajima J, Hamada T. Sequential production of Birbeck 
granules through adsorptive pinocytosis. J Invest Dermatol. 1984 
Jan;82(1):28-9. 
 
69. Juhlin L, Shelley WB. New staining techniques for the Langerhans cell. 
Acta Derm Venereol. 1977;57(4):289-96. 
 
70. Wolff K, Winkelmann RK. Ultrastructural localization of nucleoside 
triphosphatase in Langerhans cells. J Invest Dermatol. 1967 Jan;48(1):50-
4. 
 
71. Sjoborg S, Axelsson S, Falck B, Jacobsson S, Ringberg A. A new method 
for the visualization of the epidermal Langerhans cell and its application 
on normal and allergic skin. Acta Derm Venereol Suppl (Stockh). 
1978;58(79):23-30. 
 
72. Dagdeviren A, Alp H, Ors U. New applications for the zinc iodide-osmium 
tetroxide technique. J Anat. 1994 Feb;184 ( Pt 1):83-91. 
 
73. Takahashi S, Nakano Y. Immunohistochemical demonstration of 
Langerhans' cell in cholesteatoma using an antiserum against S-100 
protein. Arch Otorhinolaryngol. 1989;246(1):48-52. 
 
74. Cocchia D, Michetti F, Donato R. Immunochemical and immuno-
cytochemical localization of S-100 antigen in normal human skin. Nature. 
1981 Nov 5;294(5836):85-7. 
 
75. Fithian E, Kung P, Goldstein G, Rubenfeld M, Fenoglio C, Edelson R. 
Reactivity of Langerhans cells with hybridoma antibody. Proc Natl Acad 
Sci U S A. 1981 Apr;78(4):2541-4. 
 
76. Rowden G, Philips TM, Delovitch TL. Expression of Ia antigens by murine 
keratinizing epithelial langerhans cells. Immunogenetics. 1979;7:465-78. 
 
77. Valladeau J, Duvert-Frances V, Pin JJ, Dezutter-Dambuyant C, Vincent C, 
Massacrier C, et al. The monoclonal antibody DCGM4 recognizes 
Langerin, a protein specific of Langerhans cells, and is rapidly internalized 
from the cell surface. Eur J Immunol. 1999 Sep;29(9):2695-704. 
 
78. Tang A, Amagai M, Granger LG, Stanley JR, Udey MC. Adhesion of 
epidermal Langerhans cells to keratinocytes mediated by E-cadherin. 
Nature. 1993 Jan 7;361(6407):82-5. 
 
79. Ushiki T, Iwanaga T, Masuda T, Takahashi Y, Fujita T. Distribution and 
ultrastructure of S-100-immunoreactive cells in the human thymus. Cell 
Tissue Res. 1984;235(3):509-14. 
 
80. Harrist TJ, Muhlbauer JE, Murphy GF, Mihm MC, Jr., Bhan AK. T6 is 
superior to Ia (HLA-DR) as a marker for Langerhans cells and 
indeterminate cells in normal epidermis: a monoclonal antibody study. J 
Invest Dermatol. 1983 Feb;80(2):100-3. 
 
81. Valladeau J, Clair-Moninot V, Dezutter-Dambuyant C, Pin JJ, 
Kissenpfennig A, Mattei MG, et al. Identification of mouse langerin/CD207 
in Langerhans cells and some dendritic cells of lymphoid tissues. J 
Immunol. 2002 Jan 15;168(2):782-92. 
 
82. Mizumoto N, Takashima A. CD1a and langerin: acting as more than 
Langerhans cell markers. J Clin Invest. 2004 Mar;113(5):658-60. 
 
83. Furue M, Nindl M, Kawabe K, Nakamura K, Ishibashi Y, Sagawa K. 
Epitope mapping of CD1a, CD1b, and CD1c antigens in human skin: 
differential localization on Langerhans cells, keratinocytes, and basement 
membrane zone. J Invest Dermatol. 1992 Nov;99(5):23S-6S. 
 
84. Cotner T, Mashimo H, Kung PC, Goldstein G, Strominger JL. Human T 
cell surface antigens bearing a structural relationship to HLA antigens. 
Proc Natl Acad Sci U S A. 1981 Jun;78(6):3858-62. 
 
85. Martin LH, Calabi F, Milstein C. Isolation of CD1 genes: a family of major 
histocompatibility complex-related differentiation antigens. Proc Natl Acad 
Sci U S A. 1986 Dec;83(23):9154-8. 
 
86. van de Rijn M, Lerch PG, Knowles RW, Terhorst C. The thymic 
differentiation markers T6 and M241 are two unusual MHC class I 
antigens. J Immunol. 1983 Aug;131(2):851-5. 
 
87. Amiot M, Bernard A, Raynal B, Knapp W, Deschildre C, Boumsell L. 
Heterogeneity of the first cluster of differentiation: characterization and 
epitopic mapping of three CD1 molecules on normal human thymus cells. 
J Immunol. 1986 Mar 1;136(5):1752-8. 
 
88. Indrasingh I, Chandi G, Jeyaseelan L, Vettivel S, Chandi SM. Quantitative 
analysis of CD1a (T6) positive Langerhans cells in human tonsil 
epithelium. Ann Anat. 1999 Dec;181(6):567-72. 
 
89. Waterhouse JP, Squier CA. The Langerhans cell in human gingival 
epithelium. Arch Oral Biol. 1967 Mar;12(3):341-8. 
 
90. Yassin TM, Toner PG. Langerhans cells in the human oesophagus. J 
Anat. 1976 Nov;122(Pt 2):435-45. 
 
91. de Fraissinette A, Schmitt D, Thivolet J. Langerhans cells of human 
mucosa. J Dermatol. 1989 Aug;16(4):255-62. 
 
92. Younes MS, Robertson EM, Bencosme SA. Electron microscope 
observations on Langerhans cells in the cervix. Am J Obstet Gynecol. 
1968 Oct 1;102(3):397-403. 
 
93. Bhan AK, Fujikawa LS, Foster CS. T-cell subsets and Langerhans cells in 
normal and diseased conjunctiva. Am J Ophthalmol. 1982 Aug;94(2):205-
12. 
 
94. Chandi G, Indrasingh I, Chandi SM. Electron microscopic demonstration of 
Langerhans cells in human tonsillar epithelium. Clinical Anatomy. 
1989;2(4):271-6. 
 
 
 
 
 
95. Fokkens WJ, Vroom TM, Rijntjes E, Mulder PG. Fluctuation of the number 
of CD-1(T6)-positive dendritic cells, presumably Langerhans cells, in the 
nasal mucosa of patients with an isolated grass-pollen allergy before, 
during, and after the grass-pollen season. J Allergy Clin Immunol. 1989 
Jul;84(1):39-43. 
 
96. Hellquist HB, Olsen KE, Irander K, Karlsson E, Odkvist LM. Langerhans 
cells and subsets of lymphocytes in the nasal mucosa. Apmis. 1991 
May;99(5):449-54. 
 
97. Sato K, Hirano M. Langerhans cells in the larynx and the hypopharynx. 
Kurume Med J. 1997;44(4):297-303. 
 
98. Ferluga D, Vodovnik A, Luzar B, Cor A, Perkovic T, Gale N, et al. 
Langerhans and other immunocompetent cells in vocal cord epithelial 
hyperplastic lesions of patients with chronic laryngitis. Acta Otolaryngol 
Suppl. 1997;527:82-6. 
 
99. Moresi JM, Horn TD. Distribution of Langerhans cells in human hair 
follicle. J Cutan Pathol. 1997 Nov;24(10):636-40. 
 
100. Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and        
ultrastructural characterization of Langerhans cells and a novel, 
inflammatory dendritic epidermal cell (IDEC) population in lesional skin 
of atopic eczema. J Invest Dermatol. 1996 Mar;106(3):446-53. 
 
101. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, et  
al. Human epidermal Langerhans cells express the high affinity receptor 
for immunoglobulin E (Fc epsilon RI). J Exp Med. 1992 May 
1;175(5):1285-90. 
 
102. Hogan AD, Burks AW. Epidermal Langerhans' cells and their function in  
the skin immune system. Ann Allergy Asthma Immunol. 1995 
Jul;75(1):5-10; quiz -2. 
 
103. Bhan AK, Harrist TJ, Murphy GF, Mihm MC, Jr. T cell subsets and 
Langerhans cells in lichen planus: in situ characterization using 
monoclonal antibodies. Br J Dermatol. 1981 Dec;105(6):617-22. 
 
104. Becker J, Loning T, Reichart P, Hartmann N. Oral lichen planus: 
characterization of immunocompetent cells with hybridoma antibodies. 
Journal of Oral Pathology and Medicine. 1983;12(2):117-23. 
 
105. Rich AM, Reade PC. A quantitative assessment of Langerhans cells in 
oral mucosal lichen planus and leukoplakia. Br J Dermatol. 1989 
Feb;120(2):223-8. 
106. Gothelf Y, Hanau D, Tsur H, Sharon N, Sahar E, Cazenave JP, et al. T6 
positive cells in the peripheral blood of burn patients: are they 
Langerhans cells precursors? J Invest Dermatol. 1988 Feb;90(2):142-8. 
 
107. Wood J, O'Mahony JB, Palder SB, Rodrick ML, D'Eon P, Mannick JA. 
Circulating T6 antigen positive cells. J Invest Dermatol. 1984 
Apr;82(4):387-8. 
 
108. Casolaro MA, Bernaudin JF, Saltini C, Ferrans VJ, Crystal RG. 
Accumulation of Langerhans' cells on the epithelial surface of the lower 
respiratory tract in normal subjects in association with cigarette smoking. 
Am Rev Respir Dis. 1988 Feb;137(2):406-11. 
 
109. Yoshida A, Imayama S, Sugai S, Kawano Y, Ishibashi T. Increased 
number of IgE positive Langerhans cells in the conjunctiva of patients 
with atopic dermatitis. Br J Ophthalmol. 1997 May;81(5):402-6. 
 
110. Shelley WB, Juhlin L. Selective uptake of contact allergens by the 
Langerhans cell. Arch Dermatol. 1977 Feb;113(2):187-92. 
 
111. Goodarzi MO, Broberg TG, Lalwani AK. Lymphoma of the tympanic 
membrane in acquired immunodeficiency syndrome. Auris Nasus 
Larynx. 1998 Jan;25(1):89-94. 
 
112. Sontheimer RD, Bergstresser PR. Epidermal Langerhans cell 
involvement in cutaneous lupus erythematosus. J Invest Dermatol. 1982 
Oct;79(4):237-43. 
 
113. Zelickson AS, Mottaz J. The effect of sunlight on human epidermis. A 
quantitative electron microscopic study of dendritic cells. Arch Dermatol. 
1970 Mar;101(3):312-5. 
 
114. Grewe M. Chronological ageing and photoageing of dendritic cells. Clin 
Exp Dermatol. 2001 Oct;26(7):608-12. 
 
115. Thiers BH, Maize JC, Spicer SS, Cantor AB. The effect of aging and 
chronic sun exposure on human Langerhans cell populations. J Invest 
Dermatol. 1984 Mar;82(3):223-6. 
 
116. Alcalay J, Goldberg LH, Wolf JE, Jr., Kripke ML. Variations in the 
number and morphology of Langerhans' cells in the epidermal 
component of squamous cell carcinomas. Arch Dermatol. 1989 
Jul;125(7):917-20. 
 
117. Meissner K, Haftek M, Arlot M, Mauduit G, Thivolet J. Quantitative 
analysis of T6-positive Langerhans cells in human skin cancers. 
Virchows Arch A Pathol Anat Histopathol. 1986;410(1):57-63. 
 
118. Bergfelt L, Larko O, Lindberg M. Density and morphology of Langerhans 
cells in basal cell carcinomas of the face and trunk. Br J Dermatol. 1992 
Dec;127(6):575-9. 
 
119. Morelli AE, Sananes C, Di Paola G, Paredes A, Fainboim L. Relationship 
between types of human papillomavirus and Langerhans' cells in 
cervical condyloma and intraepithelial neoplasia. Am J Clin Pathol. 1993 
Feb;99(2):200-6. 
 
120. The ear, hearing and balance. In: Gleeson M, Browning GG, Burton MJ, 
Clarke R, Hibbert J, Jones NS, et al, editors. Scott-Brown’s 
otorhinolaryngology, head and neck surgery: 7th ed. Great Brittain. 
Hodder Arnold; 2008. p. 3395-445. 
 
121. Dhingra PL. Diseases of ear, nose and throat. 3rd ed. India: Elsevier; 
2004. p. 87-96. 
 
122. Gantz BJ. Epidermal Langerhans cells in cholesteatoma. Ann Otol 
Rhinol Laryngol. 1984 Mar-Apr;93(2 Pt 1):150-6. 
 
123. External ear and middle ear. In: Standring S, Berkovitz BKB editors. 
Gray’s Anatomy. 39th ed. Edinburgh: Elsevier Churchill Livingstone; 
2005. p. 654-5. 
 
124. Lim DJ. Tympanic membrane. Electron microscopic observation. I: pars 
tensa. Acta Otolaryngol. 1968;66(3):181-98. 
 
125. Lim DJ. Tympanic membrane. II. Pars flaccida. Acta Otolaryngol. 1968 
Dec;66(6):515-32. 
 
126. Lildholdt T, Clausen J, Cantekin EI. Ultrastructure of the tympanic 
membrane in the Rhesus monkey. J Laryngol Otol. 1983 Sep;97(9):785-
91. 
 
127. Johnson FR, McMinn RM, Atfield GN. Ultrastructural and biochemical 
observations on the tympanic membrane. J Anat. 1968 Sep;103(Pt 
2):297-310. 
 
128. Schmidt SH, Hellstrom S. Tympanic-membrane structure--new views. A 
comparative study. ORL J Otorhinolaryngol Relat Spec. 1991;53(1):32-6. 
 
129. Hentzer E. Ultrastructure of the human tympanic membrane. Acta 
Otolaryngol. 1969 Nov;68(5):376-90. 
 
130. Lim DJ. Human tympanic membrane. An ultrastructural observation. 
Acta Otolaryngol. 1970 Sep;70(3):176-86. 
 
131. McGovern FH. The elusive Henry Jones Shrapnell. Laryngoscope. 1983 
Jul;93(7):903-5. 
 
132. Forseni M, Hansson GK, Bagger-Sjoback D, Hultcrantz M. Infiltration of 
immunocompetent cells in the middle ear during acute otitis media: a 
temporal study. Am J Otol. 1999 Mar;20(2):152-7. 
 
133. Ichimiya I, Kurono Y, Mogi G. Immunological potential of the tympanic 
membrane. Observation under normal and inflammatory conditions. Am 
J Otolaryngol. 1997 May-Jun;18(3):165-72. 
 
134. Veldman JE. Immunology of cholesteatoma. Am J Otol. 1985 
Jan;6(1):22-5. 
 
135. Wang B. [Epidermal Langerhans cells in cholesteatoma]. Zhonghua Er 
Bi Yan Hou Ke Za Zhi. 1989;24(3):150-1, 89. 
 
136. Visser CE, Veldman JE, Van Dijk CM. [Immunology of cholesteatoma]. 
Ann Otolaryngol Chir Cervicofac. 1987;104(2):111-5. 
 
137. Chao WY, Jin YT, Huang CC. Langerhans cells in human middle ear 
cholesteatomas. Eur Arch Otorhinolaryngol. 1992;249(7):380-4. 
 
138. van Dijk CM, Visser CE, Veldman JE. Spatial distribution of Langerhans' 
cells and T-lymphocyte subpopulations in human tympanic membrane 
and aural cholesteatoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 
1986;52(2):143-52. 
 
139. Kahonen K, Palva T, Bergroth V, Konttinen YT, Reitamo S. 
Immunohistochemical identification of inflammatory cells in secretory 
and chronic otitis media and cholesteatoma using monoclonal 
antibodies. Acta Otolaryngol. 1984 May-Jun;97(5-6):431-6. 
 
140. Ichimiya I, Kawauchi H, Mogi G. Analysis of immunocompetent cells in 
the middle ear mucosa. Arch Otolaryngol Head Neck Surg. 1990 
Mar;116(3):324-30. 
 
141. Shinoda H, Huang CC. Localization of intercellular adhesion molecule-1 
in middle ear cholesteatoma. Eur Arch Otorhinolaryngol. 
1995;252(7):385-90. 
142. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, 
et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 
1994 Jul 1;180(1):83-93. 
 
143. Ichimiya I, Kurono Y, Mogi G. Immunology of the tympanic membrane. 
Acta Otorhinolaryngol Belg. 1995;49(2):121-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
